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Rift Valley Fever virus (RVFV) is an arthropod-borne bunyavirus that causes a zoonotic disease 
associated with abortion storms, neonatal mortality in livestock and hemorrhagic fever with a 
high case/fatality ratio in humans. To date, vaccine developments against RVF have been based 
on inactivated or attenuated strains but their widespread use has been hampered due to 
deleterious effects or incomplete protection, justifying further studies to improve the existing 
vaccines or to develop others. To address this, DNA plasmid and alphavirus replicon vector 
(VEEV) expressing RVFV Gn glycoprotein were constructed and evaluated for their ability to 
induce protective immune responses in mice against RVFV. An experimental live-attenuated 
vaccine (MP12) and its inactivated counterpart (WIV MP12) were developed to serve as 
benchmarks for comparison. Test vaccine candidates efficiently expressed the RVFV 
glycoprotein in vitro and elicited anti-RVFV antibody responses in immunized mice, as 
determined by RVFV specific ELISA, IgG isotype ELISA, and virus neutralization.  
Interestingly, these vaccine strategies elicited cellular immune responses as determined by Gn 
specific ELISPOT. More importantly these vaccines not only protected immunized mice from 
virulent RVFV when challenged via intraperitoneal route, but also conferred protection when 
challenged via aerosol route. This work is of public health significance as it describes the 
development of safe and effective vaccine candidates that have the ability to protect both 
livestock and humans against possible routes of exposure to this zoonotic threat. 
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1.0  INTRODUCTION 
Rift Valley fever (RVF) is an arthropod-borne viral zoonosis. The causative agent, Rift Valley 
fever virus (RVFV), was first discovered in the Rift Valley of Kenya in 1931 [1]. RVFV 
infections in livestock are characterized by an acute hepatitis, abortion, and high mortality rates, 
especially in new born or young animals. Human infection with RVFV typically leads to a mild 
flu-like febrile illness. However, approximately 2% of infected individuals have more severe 
complications, such as retinal degeneration, fatal hepatitis, severe encephalitis and hemorrhagic 
fever [2]. The ability of RVFV to cross geographic or national boundaries, coupled with the fact 
that RVFV replicates in a wide range of mosquito vectors, has raised concerns that the virus 
might spread further into non-endemic regions of the world. Before 1977, RVFV circulation was 
not detected beyond the Sub-Saharan countries. In addition, RVFV is a potential bioweapon 
agent [3]. However, since 1997, RVFV outbreaks have occurred in Egypt [4], Mauritania in 1987 
and 1998 [5], Saudi Arabia and Yemen [6]. In 2006–2007, RVFV outbreaks were recorded in 
Kenya, Somalia and Tanzania that resulted in human infections and deaths [7]. Thus, the ability 
of RVFV to cause explosive ‘‘virgin soil’’ outbreaks in previously unaffected regions 
demonstrates the need for prophylactic measures for this significant veterinary and public health 
threat. 
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1.1 RIFT VALLEY FEVER VIRUS 
1.1.1 RVFV structure and classification 
The family Bunyaviridae is comprised of a large group of arthropod-borne viruses distributed in 
among five genera; Bunyavirus, Phlebovirus, Nairovirus, Hantavirus and Tospovirus. Most 
viruses in this family infect vertebrates and are transmitted by arthropods such as mosquitoes, 
ticks, and sandflies with the exception of the viruses belonging to genuse Tospovirus which 
harbors plant viruses. Viruses in the Bunyaviridae family were originally classified based on 
their antigenic relationships. The International Committee on the Taxonomy of Viruses has 
designated 47 species in the Bunyavirus genus, 9 species in the Phelobovirus genus, 7 species in 
the Nairovirus genus and 22 species in the Hantavirus genus [8]. Rift Valley fever Virus 
(RVFV) is a typical member of the genus Phlebovirus. The virions of the Bunyaviridae family 
are spherical, measuring 80 to 120 nm in diameter, and have a bilayered lipid envelope with 
three circular nucleocapsids (Fig. 1). The virus genome contains three single-stranded negative 
sense RNA segments each in its own nucleocapsid. Recent studies have demonstrated that the 
RVFV possesses an icosahedral symmetry [9], and the two surface glycoproteins Gn and Gc 
(type I transmembrane proteins) are arranged as heterodimers on the surface of the virion [10]. A 
unique feature of the members of the family Bunyaviridae is the lack of matrix protein [11]. 
Recently, it has been shown that the cytoplasmic tails of the surface glycoproteins interact 
directly with the nucleoproteins of the ribonucleoprotein (RNP) complex and may be important 
for viral genome packaging [12-15]. 
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 Figure 1. Schematic representation of Bunyavirus 
RVFV is an enveloped virus with two surface glycoproteins Gn and Gc embedded in the lipid bilayer of 
envelope. L, M and S represent the large, medium and small RNA segments, respectively. 
1.1.2 Coding strategy of RVFV genes 
Virions contain a tripartite single-stranded RNA genome. The three segments are the large (L) 
segment (~6.4 kb) expressing virus RNA dependent RNA polymerase [11], medium (M) 
segment (~3.8 kb) encoding at least four proteins in a single open reading frame (ORF) out of 
which two are structural glycoproteins, Gn and Gc, and two are non-structural proteins, the 14kD 
NSm and a 78kD NSm+Gn fusion peptides [11, 16, 17]. The small (S) segment (~1.6 kb) 
encodes in an ambisense fashion the viral nucleoprotein (N) in the genomic oriteintation and the 
non-structural (NSs) protein in the anti-genomic orientation [11] (Fig.2).  
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 Figure 2. Schematic representation of RVFV genome 
RVFV has a tripartite genome comprised of large (L), medium (M) and small (S) gene segments. The L 
segment encodes viral RNA polymerase, the M segment encodes viral structural glycoproteins (Gn, Gc) 
and and a nonstructural protein (NSm), and the S segment encodes non structural small protein (NSs) and a 
nucleocapsid protein (N) 
 
Bunyaviruses replicate in the cytoplasm, and the progeny virions assemble by budding 
into the lumen of the Golgi apparatus [18]. The nucleocapsid (N) protein coats the genome 
segments to form ribonucleoproteins (RNPs). The two surface glycoproteins (Gn and Gc) are 
translated as polyproteins, which are later cleaved in the endoplasmic reticulum. A heterodimeric 
complex of the viral surface glycoproteins is required for targeting to the Golgi apparatus, since 
only Gn has the Golgi localization and retention signal [19].  
RVFV genome is transcribed and replicated only when it is complexed with RNA 
polymerase and nucleocapsid protein, forming RNP complex. The structural glycoproteins 
encoded by the M segment ORF are initially translated as polyprotein precursors for the two 
mature structural proteins that are co- and post-translationally processed. The carboxy terminal 
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parts of NSm and Gn contain signal peptides that most likely play roles in the translocation of 
Gn and Gc into the endoplasmic reticulum (ER) followed by transport into the Golgi 
compartment for virus assembly. After budding into the Golgi, virions are transported to the cell 
surface within secretory vesicles and are released when these vesicles fuse with the plasma 
membrane of the cell. 
 
1.1.3 Epidemiology and transmission 
RVFV was originally characterized in 1931 and an association of RVFV epizootics/epidemics 
with heavy rainfall and high mosquito population was reported [1]. Since 1931, RVFV 
epidemics/epizootics have followed unusually heavy rainfall or in conjunction with construction 
of dams. Water plays an important role in the life of most blood feeding arthropods since  they 
have aquatic immature larval stages. Therefore, the distribution of virus and associated outbreaks 
are linked to the presence of water.  It has now become clear that the El Niño activity can lead to 
heavy precipitation in southern and eastern Africa and was responsible for outbreaks of RVFV in 
the horn of Africa during 1997-98 [20, 21]. RVFV epizootics are characterized by long inter-
epizootic periods in a cyclical fashion. These cycles can vary from five to 15 years in areas 
experiencing rainfalls and change to 15 to 30 years in comparatively drier areas. Due to abundant 
rainfall in central and western Africa, RVFV outbreaks have a more continuous pattern, while in 
the comparatively drier northern Africa outbreaks are associated with irrigated lands.  
Several arthropods  can be experimentally infected with RVFV infection, but mosquitoes 
are important biological vectors for disease transmission [22-25]. RVFV has been isolated from 
greater than 30 different species of mosquitoes. Experimentally, North American mosquito 
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species belonging to genera Aedes and Culex are found to be highly competent for RVFV 
replication [26-28]. During inter-epizootic periods virus may be present in an endemic cycle 
between mosquitoes and livestock species and possibly gets amplified within the livestock and 
may then transmit to humans (Fig. 3). During the inter-epizootic period of RVFV infection in 
Kenya, the trans-ovarian transmission of RVFV in female mosquitoes (Aedes lineatopennis) was 
identified [29]. In dry to semiarid regions of Africa the survival of mosquitoes (Aedes sp) is 
dependent on drought-resistant eggs that remain viable for long dry seasons with below normal 
rainfall. Areas experiencing heavy rainfall where the water table is sufficiently raised promote 
virus activity with low level transmission to livestock with mosquitoes (Aedes sp). Shallow 
depressions or potholes (dambos) that are seasonally waterlogged offer an ideal environment for 
mosquito breeding, egg deposition and development of mosquito larvae [30]. 
During epizootic/epidemic RVFV cycles following heavy rainfall, there is emergence of 
large numbers of transovarially infected mosquitoes. These mosquitoes then infect the 
susceptible livestock species (cattle and sheep) that develop high-titer viremia and establish 
clinical infection leading to abortion storms and neonatal mortality. Humans acquire infection 
from percutaneous injury during handling aborted fetal materials or while performing 
necropsy/slaughter of infected animals [4, 31]. In addition, exposure to infectious aerosols in the 
laboratory and field have revealed the highly infectious nature of RVFV [32-36]. So far it has not 
been established if humans play an important role in the RVFV epizootic/epidemic cycles, but 
most likely act as dead end hosts. 
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 Figure 3. RVFV transmission cycle 
Mosquitoes transmit virus to susceptible livestock hosts leading to abortions and neonatal mortality. 
Humans acquire infection either as a result of bites from infected mosquitoes, handling aborted fetal 
materials, infectious aerosol exposure or percutaneous injury during necropsy and slaughter procedures on 
infected animals. 
1.1.4 Biology of RVFV infection 
Although many animals are susceptible to RVFV infection, the virus causes disease primarily in 
sheep, goat, and cattle.  Epizootics are often characterized by abortion storms that may occur at 
any stage of pregnancy. The incubation period may be as short as 12 hours in experimental 
infections, but usually lasts 24-36 hours or even longer in natural infections. Young animals, 
such as lambs, are highly susceptible to infection with 90-100% mortality. Once infected, lambs 
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develop a high grade fever (410C to 420C), exhibit abdominal pain and rapidly progress to death 
within 24 to 72 hours after the onset of the first clinical signs. Like lambs, newborn calves (<10 
days age) also exhibit rapid progression to death once infected [30]. Adult sheep and cattle are 
somewhat resistant to disease and exhibit fever, loss of appetite, profuse salivation, nasal 
discharge, abdominal pain and bloody or fetid diarrhea [37]. In some cases, severe jaundice can 
develop with an overall low (10-30%) fatality rate in adult animals depending upon nutritional 
status [5].  
In humans, RVFV infection is usually mild with a short incubation period of 4 to 6 days. 
Human infection is typically characterized by fever, myalgia, arthralgia, nausea, vomiting, and 
altered vision. However, in some cases, infection progresses to severe and sometimes fatal 
complications [2, 38, 39] such as retinitis, acute hepatitis, delayed onset encephalitis, and 
hemorrhagic fever that was observed in 1% of the cases in Egypt in 1977 [36]. Encephalitis is 
often associated with confusion and coma. A high incidence of retinal/ocular involvement was 
reported during the 2000 epidemic in the Arabian Peninsula [2]. The hemorrhagic syndrome 
characterized by coagulopathy, disseminated intravascular coagulation and multiple organ failure  
can develop in severely infected individuals and is the main cause of death with a 10-20% case 
fatality ratio [38]. Infected individuals have fever for two to four days and then exhibit jaundice, 
hemorrhages such as hematemesis, bloody stools (melena), hemorrhagic gingivitis, and petechial 
and purpuric cutaneous lesions. Hepatic necrosis has been one of the hallmark lesions found at 
autopsy. The meningoencephalitic syndrome is reported in some individuals and occurs one or 
two weeks after the febrile period.  
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1.2 LIVESTOCK AND PUBLIC HEALTH SIGNIFICANCE OF RVFV INFECTION 
RVFV infection in livestock was first reported as an enzootic hepatitis with extensive necrosis 
[40]. RVFV was essentially known as a disease affecting domestic animals, before the Egyptian 
epidemic in 1977 [4]. It was implicated in producing high mortality rates in new-born animals 
and abortions in pregnant animals. Only a few fatal human cases were reported before 1977. 
During RVFV epizootic in South Africa in 1950-1951, 100,000 sheep died and 500,000 aborted 
[41]. In the successive outbreaks, RVFV caused great economic losses in livestock resulting 
from mortality of domesticated animals and restrictions in trade and export of animals several 
months after the end of outbreaks.  
Human infections typically occur as a result of bites from infected mosquitoes or per-
cutaneous or aerosol exposure during handling of aborted fetal materials or the slaughtering of 
diseased animals [42]. In most human cases, the disease is manifested as a self-limiting febrile 
illness, which progresses to more serious complications in 1-2% [42] of infected individuals with 
a hospitalized case fatality of 10-30% [43]. The Egyptian outbreak in 1977 was the first outbreak 
involving huge number of human cases with an estimated 200,000 cases resulting in 623 deaths 
from severe complications of disease [36]. Later in 1987, a large outbreak of RVFV infection in 
Mauritania and Senegal affected 89,000 individuals [5]. In the Arabian Peninsula in 2000, an 
estimated 2000 cases and 245 deaths were reported [6]. Recently, in 2006-2007 outbreaks in 
Kenya, Somalia and Tanzania resulted in estimated 1062 reported human cases and 315 deaths 
resulting from that outbreak [7]. The magnitude of RVF outbreaks in human and animal 
populations and the widespread vector population highlights the importance of developing 
preventive measures to meet the challenge in the face of an outbreak in non-endemic areas of the 
world. 
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An RVFV outbreak outside the endemic countries would cause serious public health and 
agricultural problems. One study evaluated the pathways for introduction of RVFV into United 
States (U.S.) [44]. RVFV can be introduced by the movement of infected travelers, animals and 
mosquitoes. An intentional release of RVFV in an act of bioterrorism is also a serious concern 
for national security [45]. RVFV is therefore classified as Category A biodefense agent by 
Centers for Disease Control (CDC) and United States Department of Agriculture (USDA). In the 
past, a number of laboratory acquired infections have occurred by the lack of adequate biosafety 
measures [35]. Accordingly, the handling of RVFV requires high containment facilities, 
including biosafety level (BSL) 4 laboratories or BSL 3 Agcriculture + laboratories in the U.S.  
1.3 IMMUNE RESPONSE TO RVFV INFECTION 
Most viral infections trigger both innate and adaptive immune responses in an infected host. 
Although little is known about the cell mediated immune response, it is a common feature among 
bunyavirus infections that the antibody mediated immune response plays an important role in 
protection. The viral nucleoprotein appears to be immunogenic, but antibodies are also raised 
against the envelope glycoproteins Gn and Gc, which carry neutralizing epitopes [46, 47]. It is 
known that neutralizing antibodies have a protective effect against a virulent RVFV challenge 
and passive transfer of RVFV immune serum is protective against lethal RVFV disease in animal 
models [35, 48]. The induction of a neutralizing antibody response is a good approach for the 
development of RVFV vaccine. A major role in virulence is played by the non-structural protein 
NSs [49, 50]. Researchers have now unearthed the mechanisms used by RVFV NSs protein to 
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counteract the host immune response [51, 52]. It appears that NSs protein although is dispensable 
for virus production; however it plays a major role acting as an IFN antagonist. 
Although the correlates of immune protection for RVFV have not been elucidated, but 
there is strong evidence that neutralizing antibodies are a major contributor to protective anti-
RVFV immune responses. Resolution of disease in animals that survive infection correlates with 
the generation of anti-RVFV antibody responses.  In genomic analysis of the 33 RVFV strains 
collected from throughout Africa and Saudi Arabia from 1944 to 2000 revealed little viral 
diversity, with identity differences of only approximately 5% and 2% at the nucleotide and 
amino acid levels, respectively [53]. This could allow one efficacious vaccine construct to be 
employed throughout Africa, thereby potentially conferring protection against all RVF virus 
lineages. 
 
1.4 RVFV VACCINES 
No specific treatments are currently available to prevent RVFV infection. RVFV is sensitive to 
several antiviral agents and interferon treatment in vitro. Experimental administration of ribavirin 
and recombinant interferon alpha to RVFV infected rhesus macaques were as effective as 
prophylactic drugs, but the chemotherapeutic efficacy for the disease has not been demonstrated 
[54-56]. Passive antibody administration of serum or immune plasma may be effective, but 
impractical in an epizootic. The economic importance of disease in livestock industry and the 
highly pathogenic nature of the virus coupled with the absence of effective treatment against this 
zoonotic disease necessitate vaccine development to prevent the virus infection. 
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 1.4.1 Live attenuated RVFV vaccines 
A number of vaccines were developed to help control the spread of RVFV infection in livestock. 
One such vaccine, the Smithburn strain of RVFV, was developed by isolating the virus from 
mosquitoes in Uganda and serially passaging in mouse brains, has been developed as a live 
attenuated vaccine for veterinary use. [57]. Smithburn strain, created by alternative serial passage 
in mouse brains and embryonated chicken eggs was used for livestock vaccination for five years 
(1953-58) in South Africa [58]. Later, it was found that serial passages in mouse brain alone 
makes a better immunogen. Therefore, since 1958, the Smithburn strain passaged only in mouse 
brains has been used for immunization of animals in South Africa [58]. Modified live virus 
vaccine (MLVV) was produced in 1971 by amplification of Smithburn strain derived viruses for 
use in African countries which included Kenya and South Africa [58].  
In 1985, Caplen and coworkers reported generation of a live attenuated vaccine (MP12) 
from the RVFV ZH548 strain for both human and animal use. The RVFV wild type strains 
ZH548 and ZH501 isolated from human patients in Egypt were subjected to serial passages in 
the presence of the chemical mutagen, 5-fluorouracil (5FU) [59]. RVFV ZH548 was passaged 
two times in suckling mice and once in FhRL cells prior to serial passage in the presence of 5FU. 
ZH501 on the other hand underwent serial passage in FhRL cells and subsequently was subjected 
to plaque cloning in MRC-5 cells in the presence of 5FU. ZH501 was found to keep the virulent 
phenotype in mice after 16 serial passages. However, ZH548 became attenuated in mice after 5 
passages [59]. MP12 vaccine is currently in clinical trials and was derived from RVFV ZH548 
virus, which was passaged 12 times in the presence of 5FU. MP12 is a temperature-sensitive 
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mutant virus with mutations in all three RNA segments (L, M, S) [60-62]. Although previous 
study revealed that mutations in all three genomic segments of MP12 contribute to its attenuation 
phenotype in mice, further investigation in a recent study revealed that mutations in medium (M) 
and large (L) segements of MP12 are primarily responsible for its attenuation in mice [60, 63]. 
MP12 vaccination in pregnant sheep in mid to late gestation (70-100 days) induces neutralizing 
antibody response without observing any fetal abnormality [64, 65]. Although newborn lambs 
from the immunized sheep did not exhibit neutralizing antibodies against RVFV. However, 
consuming colostrum from the MP12 vaccinated dams lead to rapid development of serum 
neutralizing antibody titers (≥ 1:80) in the newborn lambs against RVFV (1:80 and more) [66]. 
Furthermore, lambs from a few days old to 3-months of age were able to mount neutralizing 
antibodies against RVFV post-MP12 vaccination [67, 68]. In an experimental study MP12 was 
found to be safe and immunogenic in more than 100 human volunteers who received the vaccine 
if administered at an adequate dose [69]. 
Another vaccine candidate, clone 13 from the RVFV 74HB59 strain, can be used as live-
attenuated vaccine. This virus was isolated in Central Africa from a patient infected with RVFV 
and it naturally lacks ~70% of an NSs ORF from RVFV S segment and is significantly 
attenuated [70]. Virus re-assortment experiments using clone 13 and RVFV strain ZH548 have 
revealed that the viruses that carry S segment from clone 13 had low virulence in mice, whereas 
viruses that harbor M and/or L segment from clone 13 were virulent in mice model. Further 
research using clone 13 revealed NSs as the virulence determining genes in mice [51]. 
Vaccination of pregnant sheep with clone 13 virus induced protective immune response without 
causing fetal defects or abortions [71]. A reassortant RVFV virus, R566 strain, that harbors a 
 13 
clone 13 S segment and M and L segments from MP12, is also being developed as a veterinary 
vaccine candidate [39].  
With the background knowledge about RVFV virulence determining gene, Bird et al. 
developed a mutant RVFV ZH501 virus using reverse genetics approach [72]. The mutant virus 
lacks NSm gene in the M segment and has green fluorescent protein (GFP) in place of NSs gene 
in the S segment. Inoculation of 1×103 PFU of this mutant virus (rRVF-ΔNSs:GFP-ΔNSm) 
resulted in the production of neutralizing antibodies 21 days post-inoculation. This vaccine was 
highly attenuated in rats. Challenge of vaccinated rats with virulent RVFV at 28th day post 
inoculation resulted in protection without development of detectable viremia [72].  
The use of reverse genetics approaches to make viral vaccines against RVFV has the 
potential to go forward into clinical trials. One of the advantages of this approach is the 
differentiation of vaccinated from infected animals (DIVA) by inserting non-viral genes in place 
of some inherent viral genes (NSs or NSm). Vaccinated animals with such mutant viruses will 
not elicit antibody responses against the deleted viral genes, but they will elicit antibodies against 
the non-viral foreign genes. 
 
1.4.2 Inactivated RVFV vaccines 
In the continuing effort to develop safe and effective RVFV vaccines, Randall et al. first reported 
that vaccinating mice with a formalin-inactivated vaccine derived from RVFV Entebbe strain 
induced neutralizing antibody titers in mice [73]. The RVFV Entebbe strain was initially isolated 
from mosquitoes in Uganda and had subsequently undergone over 150 intraperitoneal (i.p.) or 
intravenous (i.v.) passages in mice. The formalin-inactivated vaccine prepared from 
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embryonated chicken eggs or chicken cell cultures was less immunogenic than the vaccine 
derived from primary rhesus macaque or African green monkey kidney cells [73, 74]. The new 
formalin-inactivated vaccine (NDBR 103) was manufactured by amplification of the mouse 
serum master seed (Entebbe strain, 184th passage) in primary monkey kidney cells [73]. Since 
1977, more than 500 human volunteers have been vaccinated with NDBR 103 [75, 76]. A new 
lot of formalin-inactivated RVFV vaccine was manufactured by USAMRIID using a new master 
seed stock, which was prepared from two passages of the mouse serum master seed of the 
Entebbe strain in the diploid cells derived from fetal rhesus monkey lungs (FRhL-2) and named 
TSI-GSD 200 [75]. Further studies with this strain by Pittman et al. revealed that vaccination of 
human volunteers with three doses of TSI-GSD 200 resulted in the development of neutralizing 
antibody responses with a mean titer of 1:237 [77]. In addition, about 90% of the vaccinated 
individuals initially responded with antibody titers of 1:40 or more, whereas the remaining 10% 
of vaccinated individuals failed to achieve this titer and were considered non-responders [77]. 
This study further highlighted that a neutralizing antibody titer of 1:40 had a half life close to 
250 days in the positive responders [77]. Presently, a neutralizing titer of ≥ 1:40 is recommended 
for at-risk individuals who might get exposed to RVFV [75]. In addition to the a series of 
primary vaccinations, a regular booster vaccination is considered necessary for maintaining the 
protective titers [78].  
 
1.4.3 Limitations of the existing RVFV vaccines 
Although live-attenuated and formalin-inactivated vaccines are immunogenic, their widespread 
use is limited due to safety issues. The MLVV based on the Smithburn strain, is used to 
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vaccinate livestock in Africa, but suffers from major limitations such as causing pathology, 
spontaneous abortions, and teratogenic effects in animals [79, 80]. Another MLVV based on 
ZH548 strain called MP12 vaccine was expected to be developed as a single vaccine for human 
and animal use induces abortions and teratogenicity in newborn lambs when pregnant sheep are 
vaccinated [81]. This indicates that the use of MP12 in pregnant animals might result in some 
loss of offspring and or birth of severely deformed lambs or calves. In addition to the adverse 
effects of the live-attenuated vaccines, there are considerable safety concerns including 
incomplete attenuation, reversion back to a virulent form during the vaccine manufacturing 
process. Furthermore, animals vaccinated with live-attenuated RVFV strains cannot be 
differentiated from naturally infected livestock, due to induction of similar antibody responses, 
which may preclude export of these animals to non-RVFV endemic areas.  
Inactivated RVFV vaccine (TSI-GSD-200) elicits protective immunity in humans, 
however multiple booster vaccinations are required to achieve protective immunity, and perhaps 
most importantly, for many individuals, immunity rapidly wanes in the absence of follow-up 
booster vaccinations [77]. In addition, some local reactions such as swelling, pain and erythema 
were reported at the site of injection in individuals who received formalin-inactivated NDBR 103 
and TSI-GSD 200 RVFV vaccines. In addition a single case of  Guillain–Barré syndrome was 
also reported [76, 82].  
Reverse-genetics based vaccine candidates lacking some of the viral genes like NSs or 
NSm might suffer from inability to replicate efficiently in immune competent animals or 
humans. The longevity of immunity induced by these mutant viruses has not been evaluated, but 
their inefficient replication could possibly lead to less robust long-term immunity.  
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1.4.4 New approaches in RVFV vaccine development 
Given the limitation of existing RVFV vaccines, there is a need to explore alternative vaccine 
approaches for development of safe and effective global-use vaccines.  
1.4.4.1 Vaccines based on recombinant proteins 
 
Collet et al. first described the expression of RVFV envelope glycoproteins Gn and Gc in 
bacteria and vaccinia virus [83]. Vaccination of mice with these immunogens, especially the 
group that received vaccinia virus expressing RVFV glycoproteins, led to production of anti-
RVFV antibody responses and most mice were protected from virulent RVFV challenge [83]. 
Subsequently Keegan and Collett used a bacterial expression system and identified amino acid 
sequences of the antigenic determinant present on Gn protein [46]. Later Dalrymple et al. did 
some pioneering work and mapped the protective determinants of RVFV glycoproteins in RVFV 
surface glycoprotein Gn by using a vaccinia virus based expression system [84]. Besselaar et al. 
followed this work and identified antigenic domains on both Gn and Gc that play important role 
in virus neutralization [85]. Schmaljohn and coworkers used baculovirus protein expression 
system to produce RVFV Gn and Gn and showed protective efficacy of these expressed proteins 
in protecting mice from virus challenge [48]. 
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1.4.4.2 Virus like particle based RVFV vaccines 
 
Another approach for vaccine development is to use virus-like particles (VLPs) that are formed 
when the structural (envelope and/or nucleocapsid) proteins self-assemble to replication-
deficient particles [86]. RVFV VLP is composed of viral surface proteins Gn, Gc and 
nucleocapsid (N) protein [87, 88]. Näslund et al. reported the production of RVFV VLPs in 
mammalian cells by co-expressing viral structural genes along with a Renilla luciferase reporter 
minigenome [49]. These vaccines also elicited high titer neutralizing antibodies that protected 
immunized mice from virulent RVFV ZH548 challenge. Although RVFV VLPs has shown 
encouraging results however, several things need to be worked out such as lowering the 
significantly higher cost of production and selection of appropriate cell lines before they could be 
marketed. 
 
1.4.4.3 DNA based vaccines 
 
Vaccination with plasmid encoding antigens is another approach for inducing protective 
immunity against pathogens. The biggest advantage of using this vaccination strategy is that 
plasmids are extremely stable at wide temperature ranges. Therefore, a DNA-based vaccination 
strategy may be suitable for use in tropical areas, such as Africa, where access to refrigeration 
systems is sometimes difficult and where RVFV is endemic. Spik et al. showed that a series of 
four gene gun inoculations of DNA plasmids expressing RVFV Gn and Gc glycoproteins elicited 
neutralizing antibody titers (1:40 to 1:320). They also showed protection against virulent RVFV 
in mice vaccinated with the DNA plasmids [89]. A recent study using DNA plasmids in a similar 
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vaccination approach showed development of neutralizing titers ranging from 1:25 to 1:75. 
Although mice developed neutralizing titers, ~50% of vaccinated mice developed clinical 
symptoms post-challenge suggesting incomplete protection [90]. 
 
1.4.4.4 Vaccines based on Alphavirus replicon and other viral vectors 
 
Alphavirus replicon vectors are single hit vectors capable of eliciting potent systemic and 
mucosal immune responses against a wide range of pathogens, including hemorrhagic fever 
viruses, such as Lassa and Ebola [91]. Gorchakov et al. used alphavirus as a vaccine vector for 
RVFV and showed protection in mice from wild-type RVFV challenge following immunization 
with a Venezuelan equine encephalitis virus (VEEV) replicon expressing RVFV Gn [92]. 
However, little to no protection was observed in mice vaccinated with Sindbis virus (SINV) 
replicon expressing Gn and Gc [92]. The study also highlighted the failure of efficient expression 
of RVFV Gn by SINV replicon. Furthermore, immunization of mice with chimeric VEEV 
expressing truncate Gn fused to the N-terminus of VEEV E2 protein protected mice from 
virulent RVFV challenge [92]. Another study using alphaviruses showed that vaccination of 
mice with SINV (AR86) or Girdwood-based replicons expressing Gn and Gc from RVFV M 
gene segment induced protective antibody titers and protected mice from subsequent virus 
challenge [93].  
Another approach consisting of viral vectors for RVFV vaccine was based on using 
lumpy skin disease virus (LSDV), belonging to the Poxviridae family, for the expression of 
RVFV Gn and Gc proteins to protect sheep from RVFV as well as sheep poxvirus in South 
Africa [94]. These studies reflect the importance of viral vectors as promising candidates for 
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development of RVFV vaccines and can be furthered improved for both veterinary and human 
use against RVFV. 
  
1.4.5 C3d as a molecular adjuvant 
Although naked DNA is an efficient vaccination strategy, DNA immunization is not as efficient 
when used in large animal species. There are various ways to overcome this limitation, including  
codon optimization of  gene expression and use of adjuvants. C3d, the final degradation product 
of the third component of the complement protein C3 is a molecular adjuvant in a number of 
preclinical vaccine studies [95-103]. The adjuvant potential of this molecule involves C3d 
binding to the complement receptor 2 (CR2) that is located on the surface of follicular dendritic 
cells (FDC), B cells, and T cells in many animal species [103]. Molecular adjuvant C3d 
stimulates antigen presentation by FDCs and helps to maintain immunological B cell memory. 
On the surface of B cells, C3d interacts with CR2 and associates with CD19 and TAPA. CD19 
has a long intracellular tail that triggers a signaling cascade that results in cell activation and 
proliferation (Fig. 4). Furthermore, simultaneous C3d–CR2 ligation and surface immunoglobulin 
(sIg) by antigen, activates two signaling pathways that cross-talk and synergize to activate B 
cells, thereby leading to enhanced antibody secretion specifically directed to the fused antigen.  
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 Figure 4. C3d: the molecular adjuvant 
Invading microorganisms coated with C3d interact with B-cells through its surface immunoglobulin (sIg) 
and complement receptor (CR2). Co-ligation of these two receptors activate pathways that cross-talk and 
lead to activation of the B-cell thereby producing antigen specific immunoglobulins. 
1.5 CONCLUSION 
Perusal of the available literature reveals that the conventional live-attenuated and inactivated 
vaccines against RVFV, although successfully used in livestock in RVFV endemic areas have 
issues related with their safety and potency limits their widespread use. Live-attenuated vaccines 
cannot be used in pregnant animals due to the risk of abortions or birth of offspring with severe 
developmental defects. Alternatively, inactivated vaccines require multiple booster 
immunizations to achieve protective titers that increase their cost. Recent work with the advent 
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of alternative vaccination approaches holds some promise for further studies and future 
development. Among the new approaches, DNA and alphavirus replicons appear to be potential 
vaccine candidates that can be tested further. An ideal vaccine should not only protect from  
infection, but also prevent clinical symptoms and morbidity associated with infection. In this 
dissertation, I tested DNA and alphavirus replicons in homologous and heterologous vaccination 
approaches for their ability to protect against virus challenge and prevent clinical signs of RVFV 
infection in an animal model. 
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2.0  SPECIFIC AIMS 
2.1 BACKGROUND AND SIGNIFICANCE 
2.1.1 Background 
Rift valley fever virus (RVFV) is an arthropod-borne Phlebovirus that causes periodic epizootics 
and epidemics in sub-Saharan countries of Africa and in Egypt. This viral zoonosis primarily 
infects livestock resulting in neonatal mortality and abortions. However, it has been implicated 
as the cause of hemorrhagic fever, encephalitis, retinitis and fatal hepatitis in humans. Though 
currently confined to Africa and the Arabian Peninsula, RVFV has the potential to be introduced 
into other countries by mosquito transmission or contact with infected tissues and aerosolized 
material. Currently, the inactivated and the experimental live attenuated RVFV vaccines for 
humans suffer from safety, potency and cost issues. Therefore, there is an urgent need for 
developing safe and effective vaccines that rapidly elicit protective immunity against RVFV 
infection. 
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2.1.2 Significance of the study 
 
RVFV is a Class A bioterrorism agent with the potential to spread via mosquitoes or the aerosol 
route to cause disease in humans. Vaccination represents the most promising means of protecting 
humans against RVFV. DNA vaccines represent a novel means of expressing antigens in vivo, as 
it can induce both, humoral and cellular immune responses. Therefore, DNA vaccines encoding 
soluble RVFV glycoprotein linked to the multiple copies of C3d might show promise as a 
vaccine approach when administered in combination with alphavirus replicons expressing the 
soluble RVFV glycoprotein. This study not only facilitates the development of improved 
vaccines against RVFV, but also enhances our understanding of immune correlates that 
ultimately mediate protection against RVFV infection.  
2.2 HYPOTHESIS AND SPECIFIC AIMS 
The overall aim of this research project was to develop candidate vaccine strategies against Rift 
Valley fever virus using DNA and alphavirus replicons as vaccine delivery vectors. Preclinical 
studies with DNA and replicons have shown promise for further testing and optimization of these 
excellent vaccine vectors. Studies in the past using alternative vaccines against RVFV have 
provided encouraging results but were focused entirely on protection. The main focus of this 
comprehensive study was not only to test these vaccination strategies individually, but also in a 
heterologous prime-boost approach for their immunogenicity and protective efficacy against 
virulent RVFV challenge. In addition live-attenuated vaccine and inactivated RVFV vaccines 
were developed and used as strict benchmarks for comparison which was lacking in previous 
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studies. Although, protection is one aspect of evaluating vaccine efficacy, the present study was 
designed to evaluate DNA and alphavirus replicon-based vaccines in their ability to not only 
provide protection but also to prevent morbidity or clinical signs of infection. 
DNA vaccines represent a novel and safe method of expressing antigens in vivo for the 
generation of humoral and cellular immune responses with low costs of production. Previous 
work has shown that C3d, the final degradation product of the third component of complement, 
can act as an adjuvant to selectively promote antibody responses to a foreign antigen. DNA 
vaccination with antigen-C3d fusion proteins resulted in enhanced specific antibody titers as well 
as accelerated affinity maturation. Alternatively, recombinant alphavirus vectors such as VEE 
replicons have excellent potential as vaccine vectors. The viruses from which these replicon 
vectors are derived can replicate in humans, but are not associated with any disease and are 
currently being used in other vaccine strategies to elicit protective immune responses in humans. 
Therefore, the overall hypothesis of the study was that immunization with RVFV 
glycoprotein Gn on DNA and replicon vaccine platforms will elicit antigen-specific 
neutralizing antibody responses and confer some level of protection against virulent RVFV 
infection in mice. I addressed the hypothesis by the following specific aims: 
Aim 1. Construct and characterize candidate DNA and replicon vaccines in their ability to 
express RVFV glycoprotein Gn and develop benchmark live-attenuated and inactivated RVFV 
vaccines for comparison 
Aim 2. Compare candidate DNA and replicon-based vaccine strategies in their ability to elicit 
anti-RVFV immune responses 
Aim 3. Evaluate the ability of candidate vaccines in conferring protection against virulent RVFV 
challenge by parenteral routes 
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3.0  CONSTRUCTION AND VERIFICATION OF CANDIDATE DNA AND 
REPLICON VACCINES EXPRESSING RVFV GLYCOPROTEIN GN AND 
DEVELOPMENT OF BENCHMARK LIVE-ATTENUATED AND INACTIVATED 
RVFV VACCINES FOR COMPARISON 
 
This chapter was modified with permission from: 
Nitin Bhardwaj, Mark T. Heise, Ted M. Ross  
Vaccination with DNA plasmids expressing Gn coupled to C3d or Alphavirus replicons 
expressing Gn protects mice against Rift Valley fever virus 
PLoS Negl Trop Dis.2010 June 22. 4(6): e725 
Copyright © 2010 Bhardwaj et al. 
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3.1 PREFACE 
The study described in this aim was completed by Nitin Bhardwaj. The authors would like to 
thank Drs. Mike Parker and George Ludwig (USAMRIID) for providing anti-RVFV monoclonal 
and polyclonal antibodies, Dr. Robert Tesh (UTMB, Texas) for providing RVFV MP12 and Dr. 
Pierre Rollin (CDC, Atlanta, GA) for providing RVFV strain ZH501. 
3.2 ABSTRACT 
Rift Valley fever virus (RVFV) is an arthropod-borne virus associated with abortion storms, 
neonatal mortality in livestock and hemorrhagic fever or fatal encephalitis in a proportion of 
infected humans. Given the limitations of existing live-attenuated and inactivated vaccines, there 
is a need to explore alternative vaccination strategies with application for global use. To address 
this, two vaccination strategies were developed in this study based on DNA plasmid and 
alphavirus replicon. RVFV surface glycoprotein Gn was used as the vaccine antigen due to the 
presence of antigenic determinants and virus neutralizing epitopes on Gn. Well characterized 
DNA vaccine vector pTR600 was used to insert ectodomain of Gn behind the TPA leader 
sequence. C3d, a molecular adjuvant with the advantage of inducing antigen specific immune 
responses was used in conjunction with Gn to construct the DNA vaccine. Venezuelan Equine 
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Encephalitis virus (VEEV) based alphavirus replicon vaccine was developed by cloning Gn 
behind the highly efficient 26S subgenomic promoter on the RNA segment containing coding 
sequence for non-structural alphavirus proteins. Single cycle recombinant replicon particles 
expressing RVFV Gn were obtained by co-transfecting the RNA segment containing Gn with the 
helper RNA segment encoding VEEV structural genes into BHK21 cells. Both DNA plasmid 
and alphavirus replicon expressed Gn protein when tested by transfection followed by SDS-
PAGE and western blot. Benchmark live-attenuated vaccine was developed by cultivation and 
titration of RVFV MP12 in Vero cells and the whole inactivated virus vaccine (WIV) was 
developed by inactivating pre-titrated MP12 virus with beta propiolactone. 
 
3.3 INTRODUCTION 
Since the current RVFV vaccines have several shortcomings preventing their widespread use, 
new RVFV vaccine strategies need to be considered. Genetic immunization with DNA vector 
based vaccines is an attractive alternative. A DNA vaccine incorporates genetic information of 
the suitable antigen(s) which are produced by the host cells and hence the antigen presentation 
resembles natural infections by intracellular parasites stimulating immune responses. In addition 
this strategy is cost-effective and avoids the need for expensive and laborious biosafety level 
manufacturing procedures. Studies from our group and others have demonstrated that the 
molecular adjuvant C3d can significantly enhance antibody responses against DNA vaccine 
delivered antigens and thus improves the overall immunization strategy [95-103]. Among 
various advantages of DNA vaccines, one of the most important is the ability to remain stable at 
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various temperatures which helps in easy storage and transportation to different parts of the 
world, especially in developing countries [104]. Alphavirus replicons present another promising 
vaccination approach against infectious diseases [91]. The natural targeting potential of replicons 
to lymph node cells helps mount an efficient humoral and cell mediated immune response 
against the antigen in question [105-107]. In contrast to the infection produced by live virus, 
where infection spreads from one cell to another, vaccination with replicons limits the gene 
expression to the cells initially infected with the replicon particles and coupled with their single 
cycle expression profile provides excellent safety. The 26S subgenomic promoter transcribes the 
gene of interest to high levels and subsequently helps in translation of multiple copies of 
antigenic protein. A number of studies have shown RVFV glycoprotein Gn harbors virus 
neutralizing epitopes and thus this became the antigen of choice for this study [46, 48, 83, 92]. In 
this aim, the construction and expression of DNA plasmid and alphavirus replicon expressing 
RVFV Gn glycoprotein is described. In order to have a fair comparison of our vaccine 
candidates, MP12 and WIV MP12, live and inactivated vaccines, respectively, were also 
developed to serve as benchmarks.   
3.4 MATERIALS AND METHODS 
3.4.1 Plasmid DNA 
pTR600, a eukaryotic expression vector, has been described previously [100]. Briefly, the vector 
was constructed to contain the cytomegalovirus immediate-early promoter (CMV-IE) plus intron 
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A (IA) for initiating transcription of eukaryotic inserts and the bovine growth hormone 
polyadenylation signal (BGH poly A) for termination of transcription. The vector contains the 
Col E1 origin of replication for prokaryotic replication and the kanamycin resistance gene (Kanr) 
for selection in antibiotic media. The gene sequence encoding for the RVFV, isolate ZH548 
(Genbank DQ380206), Gn glycoprotein was used to PCR amplify a soluble form of Gn (Gn) 
without the transmembrane and cytoplasmic tail (Fig. 5). The Gn gene sequence was cloned into 
the pTR600 vaccine vector by using unique HindIII and BamHI restriction endonuclease sites. 
This Gn segment encoded a region from amino acids 131 to 557 (427 amino acids) and 
terminated in the sequence VAHCP. The vectors expressing Gn fused to three tandem repeats of 
the mouse homologue of C3d were cloned in frame and designated Gn-C3d, similar to constructs 
previously described [95]. Linkers composed of two repeats of four glycines and a serine 
[(G4S)2] were fused at the junctures of Gn and C3d and between each C3d repeat. Potential 
proteolytic cleavage sites between the junctions of Gn and the junction of C3d were mutated by 
ligating BamHI and BglII restriction endonuclease sites to mutate an Arg codon to a Gly codon 
[95]. The plasmids were amplified in Escherichia coli DH5a, purified by using endotoxin-free, 
anion-exchange resin columns (Qiagen, Valencia, CA, USA), and stored at -200C in distilled 
water. Plasmids were verified by appropriate restriction enzyme digestion and gel 
electrophoresis. Purity of DNA preparations was determined based on the optical density (O.D.) 
at wavelengths of 260 and 280 nm. 
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 Figure 5. Schematic representation of DNA vaccine expression construct. See section 3.4.1 for more  
details 
3.4.2 Replicons 
A soluble form of RVFV Gn lacking the transmembrane and cytoplasmic tail (see above) was 
introduced behind the 26S subgenomic promoter of the VEE replicon plasmid pVR21 as outlined 
in Figure 6. VEE replicons expressing influenza hemagglutinin were used as negative controls. 
VEE replicon plasmids, as well as capsid and glycoprotein plasmids were linearized with NotI, 
replicon and helper transcripts were generated using mMessage mMachine T7 transcription kits 
(Ambion), and transcripts electroporated into BHK-21 cells to package replicon particles as 
described previously [108]. Following packaging, the replicons underwent two rounds of safety 
testing to ensure that no detectable replication competent virus was present [93, 108] at which 
point the replicons were concentrated by ultracentrifugation through a 20% sucrose cushion and 
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titered using polyclonal antiserum against the VEE nonstructural proteins. Expression of the 
truncated RVFV Gn protein from the replicon was confirmed by western blot with a Gn specific 
monoclonal antibody (RV5 3G2-1A) generously provided by Dr. George Ludwig, USAMRIID, 
Ft. Detrick, Frederick, MD, USA. 
 
 
Figure 6. Schematic representation of VEEV replicon production. See section 3.4.2 for more details 
3.4.3 In vitro expression of the vaccine plasmids 
The human embryonic kidney cell line, 293T, was transfected (at 5x105 cells/transfection) with 
5µg of DNA by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA.) according to the 
manufacturer’s guidelines. Supernatants were collected after 72 h and stored at -200C. Cell 
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lysates were collected in 500µl of 1% Triton X-100 buffer and stored at -200C. To detect specific 
proteins in the cell supernatant, it was diluted 1:2 in SDS sample buffer (Bio-Rad, Hercules, CA, 
USA) and loaded onto a 10% polyacrylamide–SDS gel. The resolved proteins were transferred 
onto a nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) and incubated with a 1:5,000 
dilution of anti-RVFV mouse sera (kindly provided by Drs. Mike Parker and George Ludwig, 
USAMRIID) in phosphate-buffered saline (PBS) containing 0.05% Tween 20 and 5% skim milk 
powder. After an extensive washing, bound mouse antibodies were detected by using a 1:5,000 
dilution of horseradish peroxidase-conjugated goat anti-mouse antiserum and enhanced 
chemiluminescence (Amersham, Buckinghamshire, United Kingdom). 
3.4.4 Live attenuated and whole inactivated virus vaccines 
The attenuated strain RVFV MP12 (MP12) (Kindly provided by Dr. Robert Tesh, UTMB) and 
ZH501 (kindly provided by Dr. Pierre Rollin was propagated and titrated using Vero cells. A 
pre-titrated RVFV MP12 was inactivated with 1% beta-propiolactone to a final concentration of 
0.1% to make a whole virus inactivated preparation (WIV MP12). To ensure complete 
inactivation, an aliquot of inactivated virus was used to infect Vero cells and verify the lack of 
cytopathic effect.  
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3.5 RESULTS  
3.5.1 Construction and expression of Gn and Gn-C3d from DNAvaccine vectors 
Well described pTR600 plasmid was used to construct a DNA vaccine [100]. A 1281 bp gene 
segment encoding the ectodomain of RVFV Gn was successfully PCR amplified using high 
fidelity Taq polymerase under standard PCR conditions with Gn specific forward and reverse 
primers. The amplified gene segment that lacked TMD and CT regions of the glycoprotein was 
then successfully ligated with three copies of murine homologue of C3d. Restriction enzyme 
digestion of the plasmid containing unconjugated and conjugated Gn gene resulted in expected 
band sizes thus confirming the successful cloning.  
A truncated, soluble form of Gn from the RVFV isolate ZH548 alone or fused to three 
copies of murine C3d (Gn-C3d) was efficiently secreted from cells transfected with DNA 
plasmid as determined by transient transfection and western blot analysis (Fig. 7). Anti-RVFV 
antibodies used for western blot revealed that RVFV Gn migrated at an expected 45kDa 
molecular weight and the C3d fusion with Gn increased the molecular weight to 135kDa. Not 
only did the conjugation with C3d help add the adjuvant effect to the DNA vaccine but perhaps it 
also helped in efficient secretion of the conjugated protein from the transfected cells. It however 
needs to be determined if C3d conjugation has any role in stability of the expressed protein. 
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3.5.2 Construction and expression of Gn from VEEV replicon vaccine 
RVFV Gn ectodomain encoding gene (1281bp) was PCR amplified and cloned behind the 
VEEV 26S subgenomic promoter as described in Figure 6. Restriction enzyme analysis revealed 
the successful cloning of the gene into the VEEV vector. The new plasmid along with helper 
constructs was linearized and subjected to transcription as described in the materials and 
methods section before they were electroporated into BHK21 cells. This resulted in production 
of packaged replicons with a titer of 1x 109 infectious units (IU). Expression of the RVFV Gn 
protein from the replicon was confirmed by western blot with a Gn specific monoclonal antibody 
(Fig. 7). The replicons were then stored in screw cap vials at -800 C till further use. 
 
Figure 7. Expression of RVFV Gn from candidate DNA and replicon vaccines 
(Left panel) Proteins expressed from 293T cells transiently transfected with plasmid DNAs were assessed 
by SDS-PAGE and Western blot. The membrane was probed with anti-RVFV polyclonal antibody. (Right 
Panel) Proteins expressed from BHK21 cells infected with packaged VEE replicons were assessed by SDS-
PAGE and Western blot. The membrane was probed with anti-RVFV polyclonal sera. 
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3.5.3 Development of live-attenuated and inactivated virus vaccines 
3.5.3.1 Cultivation and titration of RVFV MP12 
 
RVFV MP12 virus was grown in Vero cells and the first signs of cytopathic effect (CPE) were 
seen at 24h post infection (PI) and by 60h PI 90% of CPE was seen resulting in cell sheet 
disruption (Fig. 8A). Vero cells were plated in a 6-well plate (4x105cells per well) and virus 
titration was done using plaque assay in which various dilution of virus were incubated for 1 hr 
at 370C on Vero cells followed by 2x MEM mixed with SeaKem ME agarose and supplemented 
with HEPES, FBS, antibiotics and fungicide. The plates were kept at 370 in a 5% CO2 
environment for 4 days. Plaques were visualized by fixing cells with 10% formalin and staining 
with 1% crystal violet (Fig. 8B). Titrated virus was stored in 1.0 ml aliquots at -800C till further 
use. 
 
A 
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Figure 8. Cultivation and Titration of MP12 in Vero cells 
Panel A: CPE produced by MP12 at various time points and Panel B: Plaques produced by MP12 virus at   
different dilutions 4 days PI. 
3.5.3.2 Development of whole inactivated RVFV vaccine (WIV) 
 
Pretitrated MP12 Virus (105 pfu) was mixed with 1% betapropiolactone (BPL) to achieve a final 
concentration of 0.1%. The virus-BPL mixture was kept at 40 C for 24 h on a rocking platform to 
achieve complete inactivation. An aliquot of BLP inactivated (WIV MP12) virus was tested on 
Vero cells along with MP12 virus. The live-attenuated vaccine (MP12) produced characteristic 
cytopathic effect 72 h post infection whereas no cytopathic effect was observed with WIV MP12 
vaccine (Fig. 9). 
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 Figure 9. Evaluation of BPL inactivated RVFV on Vero cells 
An aliquot of BPL-inactivated MP12 was added to a confluent monolayer of Vero cells and observed for presence or 
absence of CPE. RVFV MP12 virus was used as a positive control. MP12 virus produced CPE 72 h PI, however no 
CPE was observed with WIV MP12 and cell only control. 
3.6 DISCUSSION 
The goal of this study was to construct DNA and replicon-based vaccines and evaluate their 
ability to express RVFV Gn. The use of trunctated Gn as a vaccine antigen has been described 
previously [46, 48, 83, 92], therefore it became antigen of choice for the present study. The 
ability of molecular adjuvant C3d to present the tagged antigen by attaching to CR2 receptors on 
follicular dendritic cells (FDCs) in lymph nodes provides excellent oppurtunities for interaction 
of T and B lymphocytes with the antigen. This also helps in induction of high-titered antibody 
responses which are specific to antigen in question [109]. Within germinal centers, the role 
played by CR2 (CD21) present on B cells to generate antibody responses against protein antigens 
has been well characterized [110]. 
The use of alphavirus replicon as vaccine delivery vector against RVFV was first 
described by Gorchakov et al. [92]. They compared VEEV and Sindbis based vaccine vectors 
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expressing RVFV glycoproteins and tested their ability to elicit protective immunity against 
RVFV challenge in mice. The overall results from their study suggested that VEEV-based vector 
performance is superior to Sindbis based strategy. Later Heise and coworkers demonstrated 
efficient expression of RVFV glycoproteins using Sindbis replicons which lead to protective 
immunity against lethal RVFV challenge in mice [93]. The differences in results obtained from 
the two studies could be due to a different vector strain and or vaccination regimen. In this study, 
VEEV based replicons were used and the efficient production of RVFV Gn from packaged 
replicons corroborates the findings of Gorchakov et al. [92]. The most-promising finding from 
this study is the ability of replicon vectors to be used as potential vaccine platforms for 
veterinary/human vaccines. By introducing unique immunological tags in the packaged 
replicons, vaccination can be easily distinguished from natural infections.  
 RVFV vaccine studies in the past have focused on development of anti-RVFV immunity 
and or survival/protection data post-challenge. I believe that the use of appropriate benchmarks 
in parallel under the same experimental setting is essential to compare the true efficacy of the test 
vaccines in the. In order to achieve that I used live-attenuated virus (MP12) and developed an 
inactivated vaccine (WIV MP12) to serve as stringent benchmarks for comparison. Both live and 
inactivated vaccines are still under restricted use and account for a fair comparison of the vaccine 
candidates that I tested in the present study. Using both test vaccines and benchmarks in the 
same experimental setting not only help to ascertain the true potential of the test vaccines but 
also helps improve our understanding of anti-RVFV immunity. 
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4.0  COMPARISON OF CANDIDATE AND BENCHMARK VACCINES IN 
ELICITING ANTI-RVFV IMMUNE RESPONSES IN MICE 
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Nitin Bhardwaj, Mark T. Heise, Ted M. Ross  
Vaccination with DNA plasmids expressing Gn coupled to C3d or Alphavirus replicons 
expressing Gn protects mice against Rift Valley fever virus 
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4.1 PREFACE 
The study described in this aim was completed by Nitin Bhardwaj. The authors would like to 
thank Martha Collier, Nancy Davis, and Robert Johnston at UNC for assistance in production of 
VEE replicon particles. 
4.2 ABSTRACT 
I previous described the construction and expression of the candidate vaccines (section 3.0). To 
evaluate the potential of the DNA and replicon vectors as efficient vaccines, I conducted animal 
experiments using these vaccines which are described in this study. Both DNA and replicon 
vaccines were able to elicit anti-Gn antibody responses in immunized mice with a predominant 
bias towards Th2 immunity. The ligations of C3d to DNA vaccine resulted in an obvious boost 
in the elicited antibody levels. Most importantly DNA and replicon-based vaccination lead to 
development of high-titered neutralizing antibody responses which were comparable to those in 
the MP12 vaccine group. The replicon immunization emerged as an important strategy to elicit 
cell-mediated immune (CMI) responses. Although DNA alone did not contribute to the CMI, 
however priming with DNA and subsequent boosting did show improvement in IFN-γ mediated 
CMI. Epitope mapping of RVFV Gn ectodomain has also revealed presence of an 
immunodominant epitope (SYAHHRTLL). Heterologous DNA prime/replicon boost emerged as 
a balanced vaccination approach stimulating both humoral and CMI responses. 
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4.3 INTRODUCTION 
Alternative vaccination strategies for RVFV prevention and control have shown some promise 
for further development in light of the limitations of live and inactivated vaccines. An ideal 
vaccine elicits both humoral and cell mediated immune responses, thus preventing establishment 
of infection or removing already established infection. Studies with DNA plasmid expressing the 
RVFV M gene has shown the potential of this strategy as a good vaccination approach [89, 94, 
111]. The major advantages of DNA vaccines over other vaccine strategies have been well 
described in the past studies. However, their ability to induce protective immune responses in 
large animals often relies on other alternatives which help in enhancing and modulating the 
immune responses induced by the DNA plasmid vaccination approach. To address this, in this 
study DNA plasmid expressing RVFV Gn was tested for its ability to induce anti-RVFV humoral 
immunity and CMI when ligated with the molecular adjuvant C3d. I also used VEE replicon 
expressing the same glycoprotein either individually or in a heterologous DNA prime-replicon 
boost approach. Studies using alphavirus replicons as vaccine vectors for RVFV have been 
described in the past [92, 93]. However, no previous study has shown a direct comparison of 
DNA and alphavirus-based vectors, or an assessment of whether combining these vaccine 
strategies results in enhanced immunity or qualitative differences in the RVFV specific immune 
response. Furthermore, to date, RVFV vaccination studies have focused on antibody responses, 
and the ability of different vaccination strategies to elicit RVFV specific T cell responses has not 
been evaluated. Therefore, in this aim studies were conducted to directly compare DNA vaccines 
expressing either Gn or Gn-C3d to alphavirus vectors expressing Gn, evaluate whether 
combining these vaccines in a DNA prime/replicon boost strategy provided any advantage over 
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either vaccine on its own, and to assess the nature of the antibody and T cell response elicited by 
each of these vaccine strategies. 
4.4 MATERIALS AND METHODS 
4.4.1 Animals and immunizations 
Six-to-eight week old female BALB/c mice (Harlan Sprague- Dawley, Indianapolis, IN, USA) 
were used for inoculations. Mice, housed with free access to food and water, were cared for 
under U.S. Department of Agriculture guidelines for laboratory animals. Mice were anesthetized 
with 0.03 to 0.04ml of a mixture of 5ml of ketamine HCl (100 mg/ml) and 1ml of xylazine (20 
mg/ml). Gene gun immunizations were performed on shaved abdominal skin by using the hand-
held Bio-Rad gene delivery system as described previously [100, 112-114]. For DNA 
immunizations, mice were immunized three times at three week intervals with 2mg of DNA per 
0.5mg of 1-mm gold beads (Bio-Rad, Hercules, CA, USA) at a helium pressure setting of 400 
lb/in2. For replicon immunizations mice were given one dose at week 6 or three doses at weeks 
0, 3, and 6 of 1x105 infectious unit (IU) of replicons by foot pad route. Blood samples were 
collected at weeks 0, 2, 5, and 8 post-vaccination. A schematic of the vaccine regimen is listed in 
Table 1. Use of animals in this study was reviewed and approved by the University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC). 
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 Table 1. Vaccine groups and vaccination regimen 
 
4.4.2 Immunological assays 
Endpoint ELISA was performed on collected serum samples to assess the anti-Gn 
immunoglobulin G (IgG) response. Briefly, plates were coated with 100µl of inactivated RVFV 
MP12 overnight at 40C, blocked with 5% non-fat dry milk in PBS-T (1h) at 250C, and then 
extensively washed with PBS-T. Serial dilutions of mouse antisera were allowed to bind (1h) and 
the plates thoroughly washed with PBS-T. Subsequently, the primary antisera were detected by 
anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA, USA). The 
reaction was detected using tetramethybenzidine (TMB) substrate (Sigma, Saint Louis, MO, 
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USA) (1 h) at 250C. IgG isotypes were also assessed by ELISA as previously described [97, 
100]. The secondary antibodies specific for IgG1, IgG2a, IgG2b, IgG3 (Southern Biotechnology, 
Birmingham, AL, USA) were used at varying concentrations determined by optimization. 
4.4.3 Neutralizing antibody assays 
Antibody-mediated neutralization of RVFV ZH501 was measured using plaque reduction and 
neutralization test (PRNT) [77]. Briefly, 100 plaque-forming units (PFU)/0.1 ml of RVFV 
ZH501 was mixed with serial two-fold dilutions of heat inactivated (600C for 30 min) serum 
samples in 96-well tissue culture plates. Virus-serum mixtures were incubated at 40C overnight 
and placed into duplicate 23-mm wells (0.1ml/well) containing confluent monolayers of Vero 
cells (2x105). Cells were incubated for 1h at 370C and 5% CO2 and overlaid with nutrient 
medium containing 0.8% agar, 5% fetal bovine serum, 200U penicillin/ml, and 200mg 
streptomycin/ml. The plates were incubated at 370C and 5% CO2. After 4 days of incubation, 
cells were fixed with 10% formalin and stained with 1% crystal violet for visualization of 
plaques. The neutralizing antibody titer of a serum was considered positive at the highest initial 
serum dilution that inhibited >50% of the plaques as compared to the virus control titration. The 
whole experiment was conducted under strict BSL-3 conditions. 
4.4.4 ELISPOT assays 
The number of anti-Gn specific murine IFN-γ (mIFN-γ) secreting splenocytes was determined by 
enzyme-linked immunospot (ELISpot) assay (R & D Systems, Minneapolis, MN, USA). Briefly, 
pre-coated anti-mIFN-γ plates were incubated (250C for 1h) with RPMI (200µL) supplemented 
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with 10% fetal calf serum and then incubated with splenocytes (5x105/well) isolated from 
vaccinated mice. Cells were stimulated (48h) with peptides (15mers overlapping by 11 amino 
acids) representing the ectodomain of Gn glycoprotein. IL-2 was added to all wells (10 units/ml). 
Control wells were stimulated with PMA (+) (50 ng)/ionomycin (500 ng) or were mock 
stimulated (2). Plates were washed with PBS-T (3x) and were incubated (370C for 48h; 5% CO2) 
with biotinylated anti-mIFN-γ and incubated (40C for 16h). The plates were washed and 
incubated (250C for 2h) with strepavidin conjugated to alkaline phosphatase. Following 
extensive washing, cytokine/antibody complexes were incubated (250C for 1h) with stable 
BCIP/NBT chromagen. The plates were rinsed with dH2O and air-dried (250C for 2h). Spots 
were counted by an ImmunoSpot ELISpot reader (Cellular Technology Ltd., Cleveland, OH, 
USA). 
4.4.5 Statistics 
Differences in ELISA titers and virus neutralization titers between various vaccine groups were 
analyzed by one-way ANOVA, followed by Tukey’s multiple comparison test. Statistical results 
are represented in the figure by * (P<0.05), ** (P<0.01), *** (P<0.001). Statistical analyses were 
done using GraphPad Prism software. 
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4.5 RESULTS 
4.5.1 Anti-Gn total IgG responses 
After 3 vaccinations, mice vaccinated with DNA expressing Gn elicited anti-Gn antibodies 
(1:180), however, the fusion of C3d to Gn enhanced the anti-Gn antibodies (1:1280), while mice 
vaccinated with replicons expressing Gn (Rep-Gn) had an average anti-Gn titer of 1:2560 (Fig. 
10). There were no detectable antibodies following a single DNA vaccination (data not shown). 
In order to determine if Gn-C3d-DNA could prime and enhance antibody titers following a Rep-
Gn boost, mice were vaccinated twice with Gn-C3d-DNA and then administered a single 
inoculation of replicon expressing Gn. These vaccinated mice had higher anti-Gn antibody titers 
(1:4160) compared to mice vaccinated with a single vaccination of alphavirus-replicon (1:280). 
Mice vaccinated the Gn-DNA only, did not elicit any detectable anti-Gn antibodies (Fig. 10). 
These antibody responses were comparable to mice immunized with live attenuated RVFV 
(MP12), but 1–2 log10 lower than mice vaccinated with three doses of whole-inactivated RVFV 
(WIV MP12).  
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 Figure 10. Indirect ELISA meauring RVFV specific IgG responses in mice immunized with indicated 
vaccines 
All groups received primary and two booster immunizations (except MP12) spaced 3 weeks apart. Serum 
samples were collected two weeks after the last immunization (week 8 of the study), except for the group of 
mice vaccinated at week 0 with MP12. End point dilution titers were conducted by diluting the sera until 
the OD values reached the background levels. Each dot represents an individual mouse. Error bars denote 
the standard error within the samples with a measurable titer. Representative data from 1 of 2 experiments 
shown. A 1-way ANOVA with Tukey’s multiple comparison test was used to determine the significance of 
the data between groups, which is denoted by asterisks; *** p<0.001 for both MP12 vaccine regimens 
compared to the other vaccine regimens. 
MP12 infection elicited a mixed Th1 and Th2 response, whereas mice vaccinated with three 
doses of WIV MP12 had a Th2-restricted immune response (Fig. 11E and F). Mice vaccinated 
with Gn-C3d-DNA vaccines elicited predominately IgG1, suggesting a Th2 immune response 
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(Fig. 11B and D). In contrast, the replicons expressing Gn administered to mice three times 
elicited not only IgG1, but also IgG2a and IgG2b isotypes suggesting a mixed Th1/Th2 response 
similar to that elicited by the live attenuated MP12 vaccine (Fig. 11C). Interestingly, mice 
primed with Gn-C3d-DNA maintained an IgG1 isotype bias following a boost with Gn 
expressing replicons (Fig. 11D). These titers were specific to the Gn antigen, since controls 
(DNA plasmid with no insert and replicons expressing the influenza virus hemagglutinin) did not 
elicit anti-Gn antibodies (data not shown). 
 
Figure 11. Isotype ELISA measuring RVFV-specific IgG isotype responses in sera of mice with 
indicated vaccine regimens 8 weeks post-vaccination 
1:100 dilutions of serum samples from each vaccine group (A) to (F) were used and the results are 
represented in OD values. Each dot represents an individual mouse. Error bars denote the standard error 
within the samples with a measurable titer. Representative data from 1 of 2 experiments are shown. 
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4.5.2 Elicitation of antibodies that neutralize virus infection 
At week 8 of the study, sera from mice vaccinated with Gn-C3d-DNA or Rep-Gn neutralized 
(PRNT50) RVFV ZH501, while priming mice with Gn-C3d-DNA and then boosting with Rep-
Gn did not significantly enhance the neutralizing titers compared to Gn-C3d-DNA or Rep-Gn 
alone (Fig. 12). Mice vaccinated with the live attenuated MP12 vaccine strain had the highest 
neutralizing titers (average; 1:656–1:736) regardless if the mice were vaccinated at week 0 or 
week 6 of the study, and they were significantly higher than sera from mice vaccinated with Gn, 
Rep-Gn and WIV MP12 (p<0.05). In contrast, serum samples collected from Gn (1:22) 
vaccinated or WIV MP12 (1:8) had low virus neutralizing titers in spite of the fact that WIV 
MP12 elicited very high RVFV specific antibody levels as measured by ELISA (Fig 12). 
 
Figure 12. Neutralizing antibody responses of mice vaccinated with indicated vaccine regimens 
PRNT50 titers of week 8 sera from mice immunized with the indicated vaccines. Each dot represents an 
individual mouse. Error bars denote the standard error within the samples with a measurable titer. A 1-way 
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ANOVA with Tukey’s multiple comparison test was used to determine the significance of the data between 
groups, which is denoted by asterisks; * P<0.05. 
 
4.5.3 Elicitation of cellular immune responses 
Mice vaccinated with DNA and replicon vaccines were challenged with MP12 virus two weeks 
after the last immunization and splenocytes were collected 6 days post-infection. Cells collected 
from mice vaccinated with Gn vaccines were stimulated in vitro with 8 overlapping pools of 
peptide (15mers overlapping by 11) specific for Gn. Mice vaccinated with Rep- Gn or Gn-
C3d/Rep-Gn had responses to pools B and C (Table 2), representing a stretch of 111 amino acids 
starting at amino acid 53 in the Gn sequence. Only mice vaccinated with Gn-C3d/Rep-Gn had 
splenocyte responses to pool A. No responses were recorded from any mice to pools D-G. A few 
spots (10–12 spots) were detected following stimulation of splenocytes with an irrelevant peptide 
or left unstimulated following in vitro re-stimulation. Mice vaccinated with DNA vaccines did 
not elicit cellular responses (Table 2).  
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 Table 2. Anti-Gn cell mediated immune responses of mice vaccinated with indicated vaccine  
regimens 
 
A group of mice vaccinated with different vaccine regimens were challenged with MP12 virus at week 8 of 
the study and 6 days post-infection splenocytes were isolated and stimulated with overlapping RVFV Gn 
specific peptides (pools A to H). Each pool contained 13 overlapping peptides except pool H which 
contained 14. Responses are represented as average number of spots (SFU per million cells) from different 
vaccine groups. 
 
The peptides in these pools B and C were further analyzed to determine the peptides 
responsible for eliciting these responses in replicon-vaccinated mice. Using a matrix format, 4 
out of 10 pools (5 peptides/pool) were identified (peptide pools II, IV, VI, VII) (Table 3). From 
this analysis, four potential peptides (peptide # 18, 19, 36, 38) were identified as responsible for 
the vaccine elicited cellular responses. Two out of four peptides share a common amino acid 
sequence (SYAHHRTLL) predicted to be MHC class I restricted (www.immuneepitope.org) 
(Table 4). A unique peptide representing this region of Gn elicited similar mIFN-γ cellular 
immune response as compared to the four individual peptides as indicated in Figure 13. 
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Table 3. Peptide matrix with pool B and C peptides 
 
 
 
Table 4. Immune epitope prediction for RVFV Gn sequence 
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 Figure 13. Identification of the peptide sequence eliciting cellular immune response in mice 
vaccinated with replicons 
(A). Mice immunized with Rep-Gn vaccine were challenged with MP12 virus at week 8 of the study and 6 
days post-infection splenocytes were isolated and stimulated with overlapping RVFV Gn specific peptides 
representing pools B and C and peptide SYAHHRTLL. Responses are represented as average number of 
spots (SFU per million cells). The highlighted peptides 18 and 19 share a common amino acid sequence 
SYAHHRTLL. Representative data from 1 of 2 experiments are shown. (B). Schematic alignment of 
identified peptides with Gn. Numbers in the parentheses represent amino acid positions of the individual 
peptide. The gray box indicates the region of Gn covered by the predicted CD8+ T cells epitope 
SYAHHRTLL. 
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4.6 DISCUSSION 
One of the goals of an effective RVFV vaccine is to elicit protective neutralizing antibodies. In 
recent years, several RVFV vaccines strategies have been employed to elicit a potent neutralizing 
antibody responses [48, 49, 77, 89, 90, 92, 94], however, these vaccines did not always elicit 
high titer immune responses that protected against lethal challenge. Early RVFV vaccine studies 
focused on live-attenuated and inactivated virus strategies that induce long-lasting protection [68, 
74, 77]. However, the induction of adverse reactions may likely limit the wide spread use of live-
attenuated vaccines [79-81]. 
 To overcome the limitations discussed above, this study describes development of two 
promising vaccine candidates based on DNA plasmid and alphavirus replicon vectors that 
express the virus envelope glycoprotein, Gn. Each vaccine was tested alone or in a DNA 
prime/replicon boost strategy formulation to elicit humoral and cell mediated immune responses. 
In order to enhance the antibody responses elicited by DNA vaccines, our laboratory has 
pioneered the use of the complement protein C3d as a molecular adjuvant [97, 100, 101]. 
Vaccination of mice with DNA or replicons administered individually or in a DNA prime/ 
replicon boost strategy elicited similar anti-Gn antibody titers (Fig. 10); however, different 
subclasses of IgG were elicited by each vaccine. The isotype of the polyclonal antibody in part 
determines the effector functions of the anti-Gn antibodies and identifies the T helper cell bias 
(required for antibody class switching). The predominant IgG isotype elicited by DNA 
vaccination was IgG1 indicating a Th2 bias. However, IgG1, IgG2a, and IgG2b were detected in 
both replicon vaccinated, as well as live MP12 immunized mice, indicating that both the replicon 
and the live attenuated vaccine elicit a mixed T helper response (Fig. 11). Even though both 
MP12 infection and the WIV vaccination elicited the highest anti-Gn titers, only the live MP12 
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infection elicited strong neutralizing antibody responses. Most importantly Gn-C3d- DNA and 
Gn-C3d-DNA/Rep-Gn vaccinated mice had statistically similar neutralizing titers as MP12 
immunized mice (Fig. 12). 
 Mice vaccinated with replicons alone or in a DNA prime/replicon boost strategy, but not 
by DNA alone, had robust cellular responses directed at Gn. Cellular responses are critical for 
clearing virally infected cells in many systems. Although the elicitation of robust neutralizing 
antibodies are considered ideal for the development of an effective RVFV vaccine, induction of 
cellular responses by immunization may clear virally infected cells, reduce morbidity, and hasten 
recovery from infection. The replicon-based vaccines elicited cellular immune responses against 
the Gn protein, but Gn expressed from DNA plasmids did not, even though priming mice with 
DNA did not dampen the induction of cellular responses by the Gn-C3d/Rep-Gn in the DNA 
prime/replicon boost regimen (Table 2). Although nonspecific induction of T-cell responses 
against RVFV glycoproteins and nucleocapsid proteins have been previously reported [111], this 
is the first report to identify an MHC-I restricted immunodominant epitope (SYAHHRTLL) on 
the surface of Gn as predicted by multiple algorithm methods to detect the peptide sequence with 
lowest IC50 and hence better binding to MHC-I (Table 4) [www. immuneepitope.org].  
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5.0  EVALUATION OF THE ABILITY OF CANDIDATE AND BENCHMARK 
VACCINES TO PROTECT MICE FROM VIRULENT RVFV CHALLENGE BY 
INTRAPERITONEAL AND AEROSOL ROUTES 
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Nitin Bhardwaj, Mark T. Heise, Ted M. Ross  
Vaccination with DNA plasmids expressing Gn coupled to C3d or Alphavirus replicons 
expressing Gn protects mice against Rift Valley fever virus 
PLoS Negl Trop Dis.2010 June 22. 4(6): e725 
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5.1 PREFACE 
The study described in this aim was completed by Nitin Bhardwaj. The authors would like to Dr. 
Doug Reed from University of Pittsburgh for performing aerosol experiments. 
5.2 ABSTRACT 
RVFV has the ability to infect humans and animials by percutaneous and aerosol routes. In this 
study, I tested the ability of our vaccine candidates to protect against both intraperitoneal and 
aerosolized RVFV challenge in vaccinated mice. Both candidate vaccines were able to protect 
vaccinated mice against intraperitoneal challenge without the development of clinical illness. 
However, the groups that received DNA and replicon vaccines were partially protected following 
aerosol challenge with the same viral strain. The level of protection was similar to the group that 
received live-attenuated virus (MP12). Interestingly, DNA vaccine expressing Gn-C3d not only 
conferred complete protection in mice, but also prevented development of clinical signs post-
aerosol challenge. This is the first report of any vaccine strategy that confers complete protection 
against aerosol RVFV challenge and warrants further investigation and development. 
5.3 INTRODUCTION 
Human infection with RVFV typically manifests itself as an acute self-limiting febrile illness 
with the exception of hepatitis, severe encephalitis, hemorrhagic fever and ocular sequelae in 
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complicated cases [2]. The primary route of RVFV transmission is by mosquitoes, however the 
virus can be transmitted via aerosol inhalation [32-36]. Humans can be infected by aerosols 
generated during the slaughtering procedure, by handling aborted fetuses, performing necropsies, 
and conducting laboratory procedures. The potential for aerosolization of RVFV and the high 
morbidity and mortality associated with infection, even at low doses, has led to RVFV being 
listed as a potential bioterrorism weapon. In addition, the U.S. National Institutes of Health has 
included RVFV in their list of Category A priority agents. 
(http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/Pages/CatA.aspx).  
However, in light of this, only two studies have been performed using existing inactivated RVFV 
vaccines in protecting experimental animals from aerosolized RVFV infection [115, 116]. 
Incomplete protection after aerosol infection of mice vaccinated with inactivated RVFV vaccine 
was the outcome of both experimental studies.  
Vaccine evaluation studies in the past (with the exception of the above two studies) have 
mainly focused on survival of vaccinated mice post-intraperitoneal virus challenge [48, 49, 72, 
89, 90, 92, 94, 117]. An ideal vaccine should be able to protect from all potential routes of 
infection. In addition, an ideal vaccine will not only protect from viral infection, but also prevent 
development of clinical symptoms. In this study, we evaluated our candidate DNA and replicon 
based vaccines for the ability to confer protection, as well as the ability to prevent clinical 
symptoms using both intraperitoneal and aerosol routes for virulent virus challenge. 
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5.4 MATERIALS AND METHODS 
5.4.1 Determination of RVFV ZH501 dose for intraperitoneal challenge route 
Groups of naïve BALB/c mice were inoculated intraperitoneally (i.p.) with different 
concentrations (101 PFU to 105 PFU) of RVFV ZH501 virus. Post-infection, mice were housed 
in sealed negative-ventilation bio-containment units (Allentown Inc., Allentown, NJ, USA). All 
manipulations with infected mice and/or samples involving RVFV ZH501 were performed under 
strict BSL-3 enhanced conditions. The animals were examined twice daily for visual signs of 
morbidity or mortality. 
 
5.4.2 RVFV ZH501 challenge of vaccinated mice by intraperitoneal route 
At week 8 of the study, a challenge dose containing 1x103 PFU of RVFV ZH501 was 
administered i.p to vaccinated or control mice. During challenge, mice were housed in sealed 
negative-ventilation bio-containment units (Allentown Inc., Allentown, NJ, USA). All 
manipulations with infected mice and/or samples involving RVFV ZH501 were performed under 
strict BSL-3 enhanced conditions. The animals were examined twice daily for visual signs of 
morbidity or mortality, using a lab-validated scoring system as previously described [37]. Mice 
were observed for clinical signs that ranged from lethargy, ruffled fur, and weight loss to 
neurological manifestations, such as hind-limb paralysis. Mice found in a moribund condition 
were euthanized. 
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5.4.3 Determination of RVFV ZH501 dose for aerosol challenge  
Groups of naïve BALB/c mice were exposed to RVFV aerosols in whole-body exposure 
chambers housed within Class III biological safety cabinets maintained under negative pressure 
(-1 WC"), as previously described [118]. The animals were exposed inside a whole-body 
chamber which could contain up to four smaller stainless steel mesh restraint cages holding 
approximately 10 mice/cage or two guinea pigs/cage. The animal exposures were acute and 
lasted 30 min. A Collison nebulizer (BGI Inc., Waltham, MA) was used to generate the smaller 
(1 μm) particles. Exposure concentration, expressed in plaque-forming units (PFU)/ml, was 
determined by isokinetic sampling of the chamber with an all-glass impinger (AGI; Ace Glass, 
Vineland, NJ). DMEM medium with 3% sera w/v (Sigma, St. Louis, MO) was used to collect 
medium in the impinger. Post-challenge, mice were housed in sealed negative-ventilation bio-
containment units (Allentown Inc., Allentown, NJ, USA). All manipulations with infected mice 
and/or samples involving RVFV ZH501 were performed under strict BSL-3 enhanced 
conditions. The animals were examined twice daily for visual signs of morbidity or mortality. 
 
5.4.4 RVFV ZH501 challenge of vaccinated mice by aerosol route 
At week 8 of the study, a challenge dose containing 1x106 PFU of RVFV ZH501 was 
administered to vaccinated or control mice in whole-body exposure chambers as described 
above. Post-challenge, mice were housed in sealed negative-ventilation bio-containment units 
(Allentown Inc., Allentown, NJ, USA). All manipulations with infected mice and/or samples 
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involving RVFV ZH501 were performed under strict BSL-3 enhanced conditions. The animals 
were examined twice daily for visual signs of morbidity or mortality, using a lab validated 
scoring system as previously described [119]. Mice were observed for clinical signs that ranged 
from lethargy, ruffled fur, and weight loss to neurological manifestations, such as hind-limb 
paralysis or circling. We used a lab validated clinical scoring system as previously described 
[119]. Mice found in a moribund condition were euthanized.  
5.4.5 Passive transfer of immune sera and RVFV challenge 
Sera from vaccinated mice were diluted 1:10 in sterile PBS and 100µl of the diluted sera was 
injected (i.p.) into new, naïve BALB/ c mice. One hour following transfer, the mice were 
challenged (i.p.) with virulent RVFV ZH501 (1x103 PFU). Mice were observed daily for 8 days 
post-transfer for signs of morbidity and mortality. 
5.4.6 IgA antibody ELISA 
ELISA was performed on collected serum samples from vaccinated groups to assess the anti-Gn 
immunoglobulin A (IgA) response. Briefly, plates were coated with 100µl of inactivated RVFV 
MP12 overnight at 40C, blocked with 5% non-fat dry milk in PBS-T (1h) at 250C, and then 
extensively washed with PBS-T. Serial dilutions of mouse antisera were allowed to bind (1h) and 
the plates thoroughly washed with PBS-T. Subsequently, the primary antisera were detected by 
anti-mouse IgA conjugated to horseradish peroxidase (Bio-Rad, Hercules, CA, USA). The 
reaction was detected using tetramethybenzidine (TMB) substrate (Sigma, Saint Louis, MO, 
USA) (1 h) at 250C.  
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5.5 RESULTS 
5.5.1 RVFV ZH501 challenge dose for intraperitoneal infection 
Groups of mice were infected with different concentrations of RVFV ZH501 by intraperitoneal 
route. All mice that received virus displayed loss in original body weight except mice that 
received the lowest concentration of challenge virus (101 PFU) (Fig. 14). The loss in original 
body weight started on day 3 post-infection which coincided with mortality in the groups that 
received 103 and 104 PFU of virulent ZH501 virus (Fig. 15). Two out of five mice survived in the 
group that received 101 PFU of virus however all mice succumbed to RVFV infection by day 5 
in the rest of the groups (Fig. 15). From this pilot study the dose of 103 PFU was selected as the 
challenge dose for future use. 
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Figure 14. Weight loss curve of mice inoculated with indicated RVFV  ZH501 dose by intraperitoneal 
route 
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Figure 15. Survival of mice against intraperitoneal inoculation of indicated concentrations of RVFV 
ZH501 
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5.5.2 DNA and replicon vaccines protect mice against intraperitoneal virulent virus 
challenge 
Two weeks after final vaccination, the mice were challenged with a lethal dose (1x103 PFU) of 
RVFV ZH501. All the mice vaccinated with an all Gn-C3d-DNA or Rep-Gn strategy or in a 
DNA prime/replicon boost strategy were protected from virulent virus challenge with no body 
weight loss or development of clinical signs (Fig. 16 and Fig. 17). Sixty percent of mice that 
received Gn without the molecular adjuvant C3d displayed ruffled fur and lethargy with one 
mouse succumbing to infection (Fig. 16D). As expected, all the mice immunized with MP12 and 
then challenged with RVFV ZH501 survived lethal challenge with no clinical signs of infection 
(Fig. 17C). However, mice vaccinated with WIV MP12 were not protected from challenge with 
all mice exhibiting reduced body weight (Fig. 17C), ruffled fur, lethargy, and all mice ultimately 
succumbing to infection (Fig. 16D).  
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 Figure 16. Weight loss curves and survival against virulent RVFV challenge of mice vaccinated with 
indicated vaccine regimens 
Mice vaccinated with indicated vaccines or appropriate controls, DNA plasmid with no insert (DNA 
control) and replicon expressing influenza HA (replicon control) were challenged i.p. with 1000 PFU of 
RVFV ZH501 and monitored for loss in body weight (A) to (C) and mortality (D) daily post-challenge. 
Dead and moribund mice were included in the weight loss curves on the day of death, but not after. The 
daily weight of each mouse was compared to its weight on the day of challenge, and data are shown as the 
average percentage of initial weight for each cohort. Error bars represent the standard error for all samples 
available at that time point. A two-way ANOVA with Bonferroni’s post tests was used to determine the 
significance of the body weight data between groups, which is denoted by asterisks; *P<0.05, **P<0.01, 
*** P<0.001. All vaccinated mice showed statistically significant protection (P<0.05, log rank test) 
compared to unvaccinated mice. 
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Unvaccinated naive mice had severe signs of infection and body weight loss which resulted in all 
mice succumbing to infection by day 4 post-challenge (Fig. 16D). Mice that received appropriate 
DNA and replicon controls displayed clinical signs of infection (Fig 17A and B) and mortality 
was also observed in the control groups. 
 
Figure 17. Post-challenge sickness score in mice vaccinated with indicated vaccine regimens 
Mice immunized with indicated vaccines or appropriate controls, DNA with no insert (DNA control) and 
replicon expressing influenza HA (replicon control) (A) to (C) were challenged with 1000 PFU of RVFV 
ZH501 and monitored for clinical signs associated with RVFV infection and mortality daily post-challenge. 
(D) Mice were evaluated daily and scored for individual symptoms. Ruffled fur (absent = 0, present = 1), 
activity (normal = 0, reduced = 1), hunched (absent = 0, present = 1). The final score was the addition of 
each individual score. The minimum score was 0 for healthy and 1–3 depending upon the severity. A two-
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way ANOVA with Bonferroni’s post tests was used to determine the significance of sickness score data 
between different groups, which is denoted by asterisks; **P<0.01, *** P<0.001. 
5.5.3 Passive sera transfer protects mice from virus infection 
Pooled antiserum from each vaccinated group was transferred (i.p.) into unimmunized mice, 
which were then challenged i.p. with a lethal dose of RVFV ZH501 (Table 5). Eighty percent of 
mice that received sera from MP12 immunized mice survived challenge. A similar outcome was 
observed in the Gn-C3d group where 80% of mice survived. Sera from mice primed with Gn-
C3d-DNA and then boosted with Rep-Gn or immunized with Rep-Gn protected 40% (2/5) of 
mice, which was similar to the mice that received sera from Gn-DNA vaccinated mice. All the 
mice that received sera from WIV MP12 immunized mice or mice that received sera from 
control immunized mice (DNA control, Rep control, Naïve) succumbed to virulent RVFV 
ZH501 infection. 
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Table 5. Passive transfer of sera from vaccinated mice protects against virulent RVFV challenge 
Vaccine groups Survivors 
Gn 3/5 
Gn-C3d 4/5 
Rep-Gn 2/5 
Gn-C3d/Rep-Gn 2/5 
MP12.wk0 4/5 
MP12.wk6 5/5 
WIV MP12 0/5 
DNA control 0/5 
Rep control 0/5 
Naïve 0/5 
Mock challenged 5/5 
 
Five to six weeks old BALB/c mice were pre-treated with 100 µl of 1:10 diluted serum from the indicated 
vaccinated mice or naïve animals by intraperitoneal injection. One hour post-sera inoculation mice were 
infected with 1000 PFU of RVFV by intraperitoneal route and monitored for survival. 
5.5.4 RVFV ZH501 challenge dose for aerosol infection 
A starting dose of 106 PFU resulted in development of RVFV aerosols with a receiving end 
concentration of 1000 PFU thus suggesting a drop of 3 log10 in virus concentration during the 
aerosolization process whereas no plaques were detected in aerosolized virus sample with 105 
PFU starting dose (data not shown). Groups of female BALB/c mice were infected with RVFV 
ZH501 strain by aerosol route using two different starting virus concentrations (105 and 106 PFU) 
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as described in the materials and methods section. Mice that received 1000 PFU as the 
aerosolized virus concentration developed clinical signs of infection and first mortality was 
observed on day 6 post-infection (Fig. 18). All mice in the 106 PFU group were dead by day 10 
post-infection on the other hand, no mice from the 105 PFU group got sick or died of aerosolized 
RVFV infection (Fig. 18). A 106 PFU starting dose was employed in subsequent experiments as 
the challenge dose for aerosol RVFV infection. 
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Figure 18. Survival of mice against aerosol inoculation of indicated concentrations of RVFV ZH501 
 
5.5.5 Protective efficacy of DNA and replicon vaccines against RVFV aerosol challenge 
The mice were challenged two weeks after final vaccination with 1x106 PFU of RVFV ZH501. 
All the mice vaccinated with Gn-C3d-DNA were protected from virulent virus challenge with no 
body weight loss or development of clinical signs (Fig. 19A and C and Fig 20A). All mice that 
received Gn without the molecular adjuvant C3d displayed clinical signs of infection and 3 mice 
succumbing to infection (Fig. 20A and Fig 19C).  Surprisingly only 2 out of 5 mice immunized 
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with MP12 and then challenged with RVFV ZH501 survived lethal challenge and all showed 
clinical signs of infection (Fig 20B and Fig. 19C).  A similar result was observed with mice 
immunized with Rep-Gn alone or in prime boost fashion (Gn-C3d/Rep-Gn) where 3 out of 5 
mice succumbed to infection (Fig. 19C). Unvaccinated naive mice had severe signs of infection 
and body weight loss which resulted in all mice succumbing to infection by day 7 post-challenge 
(Fig. 19A and C).  Mice that received appropriate DNA and replicon controls displayed loss in 
body weight, clinical signs of infection, (Fig. 19 and Fig. 20) and mortality was also observed in 
the control groups (Fig. 19C). 
 
Figure 19. Weight loss curves and survival against virulent RVFV challenge of mice vaccinated with 
indicated vaccine regimens 
Mice vaccinated with the indicated vaccines or appropriate controls, DNA with no insert (DNA control) 
and replicon expressing influenza HA (replicon control) were challenged with 1000 PFU of RVFV ZH501 
by aerosol route and monitored for loss in body weight (A) and (B) and mortality (C) daily post-challenge. 
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Dead and moribund mice were included in the weight loss curves on the day of death, but not after. The 
daily weight of each mouse was compared to its weight on the day of challenge, and data are shown as the 
average percentage of initial weight for each cohort. 
 
Figure 20. Post challenge sickness score in mice vaccinated with the indicated vaccines 
Mice immunized with the indicated vaccines or appropriate controls were challenged with 1000 PFU of 
RVFV ZH501 by aerosol route and monitored for clinical signs associated with RVFV infection and 
mortality daily post-challenge. (D) Mice were evaluated daily and scored for individual symptoms. Ruffled 
fur (absent = 0, present = 1), activity (normal = 0, reduced = 1), hunched (absent = 0, present = 1), nervous 
symptoms/paralysis (absent = 0, present = 1). The final score was the addition of each individual score. The 
minimum score was 0 for healthy and 1–3 depending upon the severity.  
 72 
5.5.6 DNA vaccination elicits serum IgA response 
After 3 vaccinations, mice vaccinated with DNA plasmid expressing Gn by itself or in 
conjunction with C3d (Gn-C3d) (Fig 21). These titers were specific to the Gn antigen, since 
controls (DNA plasmid with no insert and replicons expressing the influenza virus 
hemagglutinin) did not elicit anti-Gn antibodies (data not shown).    
 
Figure 21. Indirect ELISA measuring RVFV specific IgA responses in mice immunized with 
indicated vaccines 
All groups received primary and two booster immunizations (except MP12) spaced 3 weeks apart. Serum 
samples were collected two weeks after the last immunization (week 8 of the study). Error bars denote the 
standard error within the samples with a measurable titer.  
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 5.6 DISCUSSION 
In this study, we evaluated our candidate vaccines for the ability to confer protection, as well as 
the ability to prevent clinical signs after challenge by the intraperitoneal or aerosol routes. Few 
mice from DNA and replicon control groups survived virus infection similar to previous studies 
[89, 94]. However, all of the control mice displayed clinical signs of infection that were 
characterized by ruffled fur and lethargy. We observed a correlation between neutralizing 
antibody titers (Fig. 12) and development of clinical signs or mortality in the study involving 
intraperitoneal virus challenge. To further explore the ability of factors in the sera to protect mice 
from RVFV infection by the intraperitoneal route, passive transfer of serum from vaccinated 
mice to naïve mice demonstrated that humoral immune response play a major role in anti-RVFV 
immunity [48]. Not all mice that received passively administered serum were protected, which 
may be due to dilution of the neutralizing antibodies during preparation. Mice with a PRNT50 
value of <1:10 succumbed to lethal infection and a PRNT50 value of ≥1:40 was sufficient to 
prevent clinical signs. This however, was not the case post-aerosol challenge in the vaccinated 
mice where neutralizing antibody titers did not correlate well with survival or development of 
clinical signs. This finding is in contrast to the experimental study performed by Anderson et al. 
[115]. They reported a correlation between the day 42 PRNT50 values after 3 vaccinations with 
survival. This could be explained by the fact that they performed experiments using rats and used 
formalin inactivated RVFV vaccine. However the authors did propose that serum neutralization 
antibody is not the only possible correlate of protection post-aerosol infection [115]. It should 
further be noted that a similar study performed in the past had strikingly different outcomes 
showing lack of protection in vaccinated mice after aerosol infection using same inactivated 
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RVFV vaccine [116]. This infers that the mechanism of protection after aerosol infection is not 
fully understood and demands further investigation. We evaluated pre-challenge sera from 
vaccinated mice for serum IgA levels and found that only DNA vaccination lead to development 
of any anti-RVFV serum IgA titers. Mice immunized with MP12 did not elicit IgA antibody 
reponse. This could be a general property of DNA vaccination or the route of immunization 
might also have some role in modulating IgA isotype. IgA is the most abundant immunoglobulin 
isotype produced in the body and is the second most dominant isotype in the circulation after IgG 
[120]. The function of serum IgA in development of systemic immune response has not been 
fully understood. One of its major roles might be to function as an inflammatory antibody 
through interactions with FcαR on immune effector cells [121]. I speculate that serum IgA plays 
an important role in modulating immunity to pathogens and might explain the survival of mice 
immunized with the Gn-C3d vaccine. The issue of survival from control DNA or mock 
vaccination is curious, but has been observed in previous publications. Spik et al. [89] also 
observed survival of a subset of mice following vaccination with DNA controls up to 31 days 
following challenge with Rift Valley fever virus. In addition, Bird et al. observed that sham mice 
did not succumb to lethal Rift Valley fever virus challenge, but they developed severe clinical 
signs of ruffled fur, hunched back, and lethargy [72]. In sum, the vaccination strategy employing 
Gn-C3d emerged as the promising strategy protecting animals from both i.p. and aerosol 
challenge without development of clinical signs and demands further test and evaluation in large 
animal species.  
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6.0  CONCLUSIONS AND FUTURE DIRECTIONS 
One of the major thrust areas in the prevention of RVFV infection is to design safe and effective 
vaccines. In the beginning, research was focused on developing a live-virus based vaccine to 
prevent RVFV outbreak in livestock. These early vaccines although elicited long-lasting 
immunity after single dose vaccination, however it retained the virulent potential to cause 
abortions or fetal malformations in livestock species [79-81]. Inactivated whole virus-based 
vaccines were the next to get developed with the idea of inducing good immunity without 
worrying about the potential side effects as observed with its live counterpart [77]. 
Unfortunately, the inactivated RVFV vaccines developed so far have been shown to be less 
efficacious in inducing protective immunity than the live attenuated vaccines and require 
multiple booster vaccinations to obtain immunity [77]. Studies in the recent years reflect 
continuous efforts in the development of an effective vaccine strategy against this zoonotic 
pathogen [48, 49, 77, 89, 90, 92, 94]. Although preclinical research with the new vaccine 
strategies showed some promise, several factors including higher cost of production and 
questionable safety limits their potential use.  
The recent outbreak of RVFV in Saudi Arabia and Yemen reflects the ability of this 
pathogen to create virgin soil epidemics [6, 38, 122]. In addition, high morbidity and mortality 
associated with RVFV infection poses a continuous threat of its malicious use by terrorist groups 
as a biological weapon [39, 44, 45, 123]. Therefore, there is a pressing need for developing 
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RVFV vaccines that optimally combine efficacy and safety for human and veterinary use. To 
address this issue, the present research study was undertaken, focused on development and 
testing of two promising RVFV vaccine candidates based on DNA and alphavirus replicon 
vectors that express the virus envelope glycoprotein, Gn. Since current diagnostic tests employ 
RVFV recombinant N protein based ELISA [124-126]. Therefore, an ideal RVFV vaccine, 
especially for livestock applications, would lack the RVFV N protein, which would allow 
differentiation between vaccinated and infected individuals. As a benchmark to compare the test 
vaccines, a live-attenuated (MP12) and whole inactivated virus (WIV MP12) vaccines were also 
developed in this study. 
DNA vaccines have been licensed for veterinary use. However, they were found to be 
less effective in human clinical trials for other infectious diseases [127, 128]. In order to enhance 
the immunogenicity of DNA vaccines by enhancing the antibody responses directed at the 
antigen, I used a molecular adjuvant C3d which has shown positive results in previous studies 
[97, 100, 101]. Since the Gn glycoprotein is known to contain protective neutralizing epitopes 
[46, 48], my efforts were focused on characterizing whether fusion of the C3d molecule to Gn 
resulted in enhanced RVFV specific immunity. Each vaccine was tested alone or in a DNA 
prime/replicon boost strategy formulation to elicit protective immune responses against virulent 
RVFV infection in mice. The development of marker vaccines make it possible to differentiate 
infected from vaccinated animals [129]. To address issues associated with potential RVFV 
exposure in the real world scenario, both intraperitoneal (i.p.) and aerosol routes of virus 
challenge were employed in this study. 
Mice vaccinated with Gn-C3d vaccine had high titer neutralizing antibodies compared to 
mice vaccinated with DNA expressing Gn alone. It remains to be determined whether this effect 
 77 
is solely due to C3d’s function as a molecular adjuvant or whether the fusion of C3d also 
enhances the secretion of Gn from the cell or the protein’s stability in the extracellular 
environment. In addition to the DNA vaccine strategy, I also used a DNA prime/alphavirus 
replicon boost strategy to expand the repertoire of elicited immune responses. Previously Heise 
et al. used a Sindbis virus replicon vectors expressing the RVFV Gn and Gc glycoproteins, as 
well as the non-structural NSm protein to induce protective immune responses in mice against 
RVFV [93]. Studies in the past have mainly focused on survival of vaccinated mice post-
challenge. However, an ideal vaccine should not only be able to protect from virus infection, but 
also prevent development of clinical symptoms. In this study, I evaluated candidate vaccines for 
the ability to confer protection, as well as ability to prevent clinical signs.  
DNA or replicon vaccination individually or in a heterologous approach elicited identical 
total IgG antibody titers but different IgG isotypes (Fig. 10 and Fig. 11). DNA immunization 
resulted in a predominantly Th2 biased immune response indicated by predominant IgG1 isotype 
in prechallenge sera. Replicon and live attenuated vaccine (MP12) elicited a mixed helper T cell 
response indicated by the detection of IgG1, IgG2a, and IgG2b isotypes (Fig. 11). Among 
benchmark vaccines, only the live MP12 infection elicited strong neutralizing antibody 
responses, however despite of higher total anti-Gn IgG titers, WIV MP12 failed to elicit 
noticeable neutralizing antibody titers (Fig. 12). Most importantly, mice vaccinated with Gn-C3d 
and Rep-Gn had neutralizing antibody titers that were statistically identical to the titers of MP12 
group (Fig. 12). The issue of survival from control DNA or mock vaccination is curious, but has 
been observed in previous publications. Spik et al. [89] also saw survival of a subset of mice 
following vaccination with DNA controls up to 31 days following challenge with Rift Valley 
fever virus. In addition, Bird et al. observed that sham mice did not succumb to lethal Rift Valley 
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fever virus challenge, but they developed severe clinical signs of ruffled fur, hunched back, and 
lethargy [72]. Another interesting observation was the results from passive sera transfer 
experiment suggesting the important role played by factors in serum in conferring protection 
against i.p. RVFV infection (Table 5). A correlation between neutralizing antibody titers and 
development of clinical signs/mortality were observed when vaccinated mice were challenged by 
i.p. route. This was reflected in the observation that mice with a PRNT50 value of <1:10 
succumbed to RVFV infection and a PRNT50 value of ≥1:40 was sufficient to prevent clinical 
signs or body weight loss after i.p. challenge (Fig. 16 and Fig. 17)  
On the other hand, vaccinated mice challenged by aerosol route had an interesting 
outcome where morbidity/mortality was found not to correlate with the PRNT50 values. 
Anderson et al. reported similar finding in their study where the inactivated vaccine that 
conferred almost complete protection by i.p. challenge failed to protect mice from aerosol virus 
challenge [116]. The group of mice immunized with Gn-C3d vaccine was the only group that 
displayed complete protection against aerosol challenge with virulent RVFV. Despite higher 
neutralizing antibody titers, the MP12 group had some mortality associated with aerosol 
challenge (Fig. 19). Although the complete function and role of serum IgA is not fully 
understood, but I speculate that serum IgA plays an important role in defense against pathogens 
and might explain this outcome since only DNA immunization produced detectable serum IgA 
levels (Fig. 21). Induction of serum IgA could be a general property of DNA-based vaccination 
and further experiments are required to corroborate these findings.  
Elicitation of high-titered neutralizing antibody responses are considered one of the 
important features in vaccine development. However, an ideal vaccine would also induce cellular 
immunity. Cell-based immune responses would help clear virally infected cells thereby limiting 
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virus production and hasten recovery. In the present study, cellular immune responses directed 
towards RVFV Gn were observed only with Rep-Gn group. DNA-based immunizations did not 
induce any cellular immunity (Table 2). In addition this is the first report identifying a MHC-I 
restricted T cell epitope SYAHHRTLL in RVFV glycoprotein Gn (Table 4 and Fig. 13). This 
immunodominant epitope on the surface of Gn might play an important role in anti-RVFV 
immunity. However further studies are required before any such associations are made. 
The study presented here demonstrates the efficacy of candidate vaccines against RVFV 
infection in mice. The results are encouraging and warrant further testing the efficacy of these 
vaccine candidates in livestock such as sheep and cattle. 
 
6.1 SUMMARY OF THE FINDINGS 
The present study describes the use of DNA and alphavirus replicon based vaccination 
approaches to elicit a protective immune response against RVFV. While both vaccines elicited 
high titer antibodies, DNA vaccination elicited high titer neutralizing antibodies, whereas the 
replicon vaccine elicited cellular immune responses. Both strategies alone or in combination 
elicited immune response that completely protected against not only mortality, but also illness 
against virus challenge. Further testing of the vaccine candidates resulted in DNA vaccination 
emerging as the single vaccine strategy conferring complete protection against aerosolized 
RVFV challenge. Even though the delivery vectors elicited some protection on their own, they 
did not prevent severe morbidity. These promising vaccines provide an alternative RVFV 
vaccine for livestock and humans. 
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 6.2 PUBLIC HEALTH SIGNIFICANCE 
Rift Valley fever virus (RVFV) is associated with abortion storms, neonatal mortality in 
livestock and hemorrhagic fever with a high case/fatality ratio in humans. In addition, it is a 
potential biowarfare agent which is a highly infectious via aerosol route. Several limitations 
prevent the widespread use of live and inactivated RVFV vaccines in livestock or humans. 
The present study demonstrates DNA expressing Gn-C3d and alphavirus replicons 
expressing Gn administered alone or in a DNA prime/replicon boost provide comparable 
protection as the live-attenuated MP12 vaccine. In addition, the vaccines prevented the 
development of clinical signs of infection. Gn-C3d emerged as the best vaccine vaccine 
candidate providing complete protection against both intraperitoneal and aerosol virus 
challenge. Encouraging results obtained from this study not only test the potential of DNA 
and replicons as efficient vaccines, but also improves our knowledge in vaccine design and 
immunity against this significant veterinary and public health threat. 
 
6.3 FUTURE DIRECTIONS 
The study presented in this dissertation demonstrates development of an improved and 
efficacious vaccination strategy against RVFV. Both DNA and replicon vectors have good 
potential to be used and licensed as common vaccines for both human and livestock. However, 
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further testing of these vaccines in non-human primates and large animal species such as sheep 
and cattle will be required and constitute the future direction for this project. 
Recent research on developing prophylactic and medical interventions against RVFV has 
increased in the past few years. However we still lack information about correlates of protection 
against RVFV infection. Additional studies with knockout mice or mice immune deficient in a 
specific immune function would help address this and provide information about the host factors 
involved in anti-RVFV immunity. Results from this study highlight the role of serum factors in 
protecting mice against RVFV infection. However we still do not know if cell-mediated 
immunity plays any role in preventing infection.  
How RVFV induces pathogenesis is one of the areas in RVFV research that still lacks a 
good understanding. We can specifically target certain genes/proteins to develop efficient 
treatment or control strategies against RVFV with the better understanding of the disease process 
and its effect on host immune system. Future studies looking at the pathogenesis and immune 
activation against RVFV infection would help design and test therapeutics and vaccines against 
this biological threat. 
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